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Lipotoxicity refers to the cytotoxic effects of excess fat accumulation in cells and it has been 
implicated as one of the contributing factors to diseases like obesity, diabetes and non-alcoholic 
fatty liver. Macroautophagy (referred to as autophagy hereafter in this thesis) is an 
evolutionarily conserved and regulated catabolic process where cellular components (proteins, 
lipids and organelles) are sequestered in double membrane vesicles called autophagosomes 
which fuse with lysosomes for degradation by lysosomal enzymes. At present, the lipotoxic 
effects of free fatty acids (FFAs) have been well studied, while the role of FFAs in the 
regulation of autophagy is still controversial. In the first part of our study we sought to examine 
effects of palmitic acid (PA) and oleic acid (OA), two of the most common dietary FFAs on the 
autophagic process. We found that PA, but not OA, was able to cause an increase in autophagic 
flux, evidenced by LC3-II accumulation and formation of Green Fluorescent Protein (GFP)-LC3 
puncta. Notably, PA-induced autophagy was found to be independent of the Mechanistic Target 
of Rapamycin Complex 1 (MTORC1) regulation. Next, in search of the mechanism mediating 
PA-induced autophagy, we found increased levels of diacylglycerol (DAG) species and Protein 
Kinase C (PKC) activation in PA-treated cells; and inhibition of classical PKC isoforms (PKC-α) 
was able to effectively suppress PA-induced autophagy. Finally, we showed that inhibition of 
autophagy sensitized the cells to PA-induced apoptosis, suggesting the pro-survival function of 
autophagy induced by PA. Taken together, results from this study reveal a novel mechanism 
underlying free fatty acids-mediated autophagy. Furthermore, the pro-survival function of 
autophagy suggests that modulation of autophagy as a potential therapeutic strategy in 
protection of cells against lipotoxicity and lipid-related metabolic diseases 
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In the second part of our study, we tried to investigate how modulation of endogenous saturated 
and monounsaturated fatty acids (MUFAs) would affect cellular autophagic activity. Stearoyl-
CoA Desaturase 1 (SCD-1) is an endoplasmic reticulum bound enzyme that catalyzes formation 
of the first double bond at the cis-Δ9 position of saturated fatty acids (SFA) to form 
monounsaturated fatty acids (MUFA). There is increasing evidence indicating that autophagy 
plays an important role in regulating lipid metabolism, while little is known whether key 
enzymes of lipogenesis like SCD-1 can regulate autophagy. In this study, we examined the roles 





(MEFs) possessing constitutively active MTORC1 as a cellular model. TSC2 (also 
known as tuberin) forms a stable complex by interacting with TSC1 (also known as hamartin) 
and this TSC1-TSC2 complex act as a GTPase-activating protein (GAP) in cells by inhibiting 
the activity of the GTPase protein Rheb (Ras homolog enriched in brain) which is a direct 
upstream activator of MTOR. Therefore, cells that have lost the functional TSC1-TSC2 complex 
are known to possess constitutively activated MTORC1 signaling pathway independent of 
growth factors regulation. We found that mRNA and protein levels of SCD-1 are significantly 
elevated in the Tsc2
-/-
 MEFs compared to Tsc2
+/+
 MEFs, resulting in significant increase in 
levels of various lipid classes. Furthermore, inhibition of SCD-1 activity by either a chemical 
inhibitor or genetic knockdown resulted in an increase of autophagic flux only in the Tsc2
-/-
 
MEFs. Induction of autophagy was independent of MTORC1 regulation as MTORC1 activity 
was not suppressed by SCD-1 inhibition. Loss of phosphorylation on Akt-S473 was observed 
upon SCD-1 inhibition and such Akt inactivation was due to disruption of membrane lipid raft 
formation, without affecting the formation and activity of MTORC2. Increased nuclear 
translocation of FoxO1 was observed following Akt inactivation, leading to increased 
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transcription of genes involved in the autophagic process. The Tsc2
-/-
 MEFs were more 
susceptible to apoptosis induced by SCD-1 inhibition and blockage of autophagy sensitized the 
cell death response. These results thus reveal a novel function of SCD-1 on regulation of 
autophagy via lipogenesis and the lipid rafts-Akt-FoxO1 pathway. In summary, in this study we 
have shown conclusively that treatment of cells with exogenous FFAs like PA but not OA 
induces autophagy via activation of PKC-  signaling pathway. Furthermore, autophagy can also 
be induced by modulating endogenous FFAs levels through inhibition of SCD-1 in cells with 
hyperactivated MTORC1 signaling pathway. Data from this study support the notion that 
changes in the intracellular levels of lipid species play important roles in regulation of 
autophagy and such inducible autophagy generally serves as a pro-survival mechanism against 
the lipotoxicity. Therefore, results from our study suggest that manipulation of autophagy can be 
a potential therapeutic strategy against different types of diseases. Induction of autophagy upon 
lipotoxic stresses can be utilized to promote cell survival and limit the cytotoxic effects of 
excess intracellular lipid accumulation while on the other hand; inhibition of autophagy can also 
be utilized in tandem with SCD-1 inhibition to target cells with hyperactivated MTORC1 










List of Figures 
Figure 1: Summary of the different stages of the autophagy process in mammalian cells 3 
  
Figure 2: Common signaling pathways involved in the regulation of autophagy 5 
  
Figure 3: Summary of the different groups of lipid species that have been identified 14 
  




Figure 5: Constitutively activated MTORC1 leads to elevated levels of de novo 
lipogenesis through activation of SREBP-1 
40 
  
Figure 6: PA treatment induces autophagy 59 
  
Figure 7: PA induced autophagy is dependent on the canonical autophagy machinery 62 
  
Figure 8: PA-induced autophagy is independent of the MTORC1 regulation 65 
  








Figure 11: PA and OA treatment induce differential accumulation of intracellular DAG 





Figure 12: PA and OA treatment induce differential accumulation of intracellular DAG 




Figure 13: PA-induced autophagy requires the activation of PKC family 76 
  
Figure 14. Activation of PKC-α is required for PA-induced autophagy 80 
  
Figure 15. OA treatment does not induce autophagy in DGAT1 knockdown MEFs 82 
  
Figure 16. Autophagy acts as a cell survival mechanism against lipotoxicity caused by PA 84 
  




Figure 18: Enzymes involved in de novo lipogenesis pathways and neutral lipids are 









Figure 20: Inhibition of SCD-1 enzymatic activity by CAY induces autophagy that is 





Figure 21: Inhibition of SCD-1 activity by CAY results in decrease of unsaturated fatty 
acid chains in DAG and TAG.  
100 
  
Figure 22: Induction of autophagy by inhibition of SCD-1 enzymatic activity can be 







Figure 23: Inhibition of SCD-1 enzymatic activity does not affect MTORC2 formation and 
activity but inhibits Akt protein activation 
108 
  
Figure 24: Inhibition of Akt protein activation in the Tsc2
-/-
 MEFs can be rescued by the 





Figure 25: Inhibition of SCD-1 enzymatic activity disrupts lipid rafts and reduces Akt 









Figure 27: Activation of FoxO1 is required for autophagy induction caused by SCD-1 





Figure 28: Activation of FoxO1 transcriptional activity is required for autophagy induction 







 MEFs are more susceptible to cell death induced by SCD-1 inhibition 
and autophagy acts as a cell survival mechanism 
131 
  
Figure 30: Summary of the proposed signalling pathways involved in PA-mediated 
autophagy and its pro-survival role in PA-induced apoptosis and lipotoxicity 
140 
  
Figure 31: Proposed mechanisms underlying the ccritical role of SCD-1 in autophagy 






List of Abbreviations 
ACC     Acetyl-CoA Carboxylase 
ACL     ATP Citrate Lyase 
AMPK     AMP-Activated Protein Kinase 
BSA     Bovine Serum Albumin 
CAY     CAY-10566 
CE     Cholesteryl Ester 
CHO     Water Soluble Cholesterol 
CMA     Chaperone Mediated Autophagy 
CQ      Chloroquine 
CTxB     Cholera Toxin Subunit B 
DAG     Diacylglycerol  
DEPTOR    DEP Domain containing MTOR Interacting Protein  
DGAT1    Diacylglycerol Acyltransferase 1 
DMEM    Dulbecco’s Modified Eagle’s Medium 
DOX     Doxycycline 
DRF      Detergent Resistant Fraction 
DSF     Detergent Soluble Fraction 
EBSS     Earles’ Balanced Salt Solution  
ER     Endoplasmic Reticulum 
ERK     Extracellular Signal-Regulated Kinase 
EV     Empty Vector 
FASN      Fatty Acid Synthase 
xvi 
 
FBS     Fetal Bovine Serum 
FB1     Fumonisin B1  
FFA     Free Fatty Acid 
FM     Full Medium 
GAP     GTPase-Activating Protein 
GAPDH    Glyceraldehyde-3- Phosphate Dehydrogenase 
GFP      Green Fluorescence Protein  
HLH-LZ    Helix-Loop-Helix Leucine Zipper 
HFD     High Fat Diet 
HPLC     High Performance Liquid Chromatography 
IP     Immunoprecipitation 
IP3     myo-Inositol 1,4,5-Triphosphate  
IRS-1     Insulin Receptor Substrate-1 
JNK     c-Jun N-Terminal Kinase 
KO     Knock-out     
LC3      Microtubule-Associated Protein 1 Light Chain 
LD     Lipid Droplet 
MAM     Mitochondria-Associated ER Membrane 
MBCD     Methyl-β-Cyclodextrin  
MEF     Mouse Embryonic Fibroblasts 
mLST8    Mammalian Lethal with Sec-13 Protein 8  
MRM     Multiple Reaction Monitoring 
MTOR     Mechanistic Target of Rapamycin 
xvii 
 
MTORC1     Mechanistic Target of Rapamycin Complex 1 
MTORC2     Mechanistic Target of Rapamycin Complex 2 
MUFA      Monounsaturated Fatty Acid  
NDRG     N-myc Downstream-Regulated Gene  
NPC     Niemann-Pick Type C 
OA      Oleic Acid 
PA      Palmitic Acid  
PARP     Poly(ADP-ribose) Polymerase  
PBS     Phosphate Buffer Saline  
PC     Phosphatidylcholine  
PDK1      Phosphoinositide-Dependent Kinase-1 
PE     Phosphatidylethanolamine; 
PG      Phosphatidylglycerol 
PhA      Phosphatidic Acid  
PI      Phosphatidylinositol 
PI3K      Phosphatidylinositol-3-Kinase 
PIP2     Phosphatidylinositol (4,5)-Biphosphate 
PIP3     Phosphatidylinositol (3,4,5)-Triphosphate 
PKC     Protein Kinase C 
PLC     Phospholipase C 
PLD1     Phospholipase D1 
Protor1/2    Protein Observed with Rictor 1/2 
PS      Phosphatidylserine 
xviii 
 
PtdIns3P    Phosphatidylinositol-3-Phosphate  
PUFA     Polyunsaturated Fatty Acid 
PVDF     Polyvinylidene Difluoride  
RAPTOR    Regulatory-Associated Protein of MTOR  
Rheb     Ras Homolog Enriched in Brain 
RICTOR    Rapamycin-Insensitive Companion of MTOR 
ROS     Reactive Oxygen Species 
SCD-1     Stearoyl-CoA Desaturase-1  
SFA     Saturated Fatty Acid 
Sin-1     Stress Activated Map Kinase Interacting Protein 1 
siRNA     short interfering RNA 
SK1     Sphingosine Kinase 1 
SREBP-1    Sterol Regulatory Element-Binding Protein 1  
S1P     Sphingosine-1-Phosphate 
TAG     Triacylglycerol  
TCA     Tricarboxylic Acid 
TET     Tetracycline 
TFEB     Transcription Factor EB  
TPA     12-O-tetradecanoylphorbol-13-acetate 
TSC      Tuberous Sclerosis Complex  
UPR     Unfolded Protein Response 
UVRAG    Ultraviolet Irradiation Resistance-Associate Gene  
WT     Wild-Type 
xix 
 
List of Publications 
1. Tan, S.H., Shui, G., Zhou, J., Shi, Y., Huang, J., Xia, D., Wenk, M.R., and Shen, H.M 
(2013). Critical role of SCD-1 in autophagy regulation via lipogenesis and lipid rafts-
coupled Akt-FoxO1 signalling pathway. (Manuscript Under Review)  
 
2. Tan, S.H., Shui, G., Zhou, J., Li, J.J., Bay, B.H., Wenk, M.R., and Shen, H.M. (2012). 
Induction of autophagy by palmitic acid via protein kinase C-mediated signaling 
pathway independent of mTOR (mammalian target of rapamycin). J Biol Chem 287, 
14364-14376. 
 
3. Zhou, J., Tan, S.H., Codogno, P., and Shen, H.M. (2013). Dual suppressive effect of 
mTORC1 on autophagy: tame the dragon by shackling both the head and the tail. 
Autophagy. 9, 803-5. 
 
4. Zhou, J., Tan, S.H., Nicolas, V., Bauvy, C., Yang, N.D., Zhang, J., Xue, Y., Codogno, P., 
and Shen, H.M. (2013). Activation of lysosomal function in the course of autophagy via 
mTORC1 suppression and autophagosome-lysosome fusion. Cell Res. 23, 508-23. 
 
 
5. Zhou, J., Hu, S.E., Tan, S.H., Cao, R., Chen, Y., Xia, D., Zhu, X., Yang, X.F., Ong, 
C.N., and Shen, H.M. (2012). Andrographolide sensitizes cisplatin-induced apoptosis via 







1.1.1 Introduction  
There are three main types of autophagy: macroautophagy, microautophagy, and 
chaperon-mediated autophagy (CMA). Macroautophagy (referred to as autophagy 
hereafter in this thesis) is an evolutionarily conserved and regulated catabolic process 
where cellular components (proteins, lipids and organelles) are sequestered in double 
membrane vesicles called autophagosomes which fuse with lysosomes for degradation by 
lysosomal enzymes (He and Klionsky, 2009; Mehrpour et al., 2010; Mizushima, 2007; 
Mizushima et al., 2008; Ravikumar et al., 2010b). The degraded macromolecules are then 
recycled back to the cytoplasm for maintaining cellular homeostasis. 
1.1.2 Stages of the autophagic process 
Our knowledge of the molecular machinery of autophagy has been greatly facilitated by 
studies done on the budding yeast Saccharomyces cerevisiae in which more than 30 ATG 
(autophagy-related genes) have been identified and many orthologs have been discovered 
in mammals (He and Klionsky, 2009; Nakatogawa et al., 2009). This has allowed the 
dissection of the whole autophagy process into several sequential steps that are regulated 
by the hierarchical function of the ATG proteins. Figure 1 below shows the summary of 
the different stages of autophagic process as described below (Rubinsztein et al., 2012a). 
These steps include:  
(i) induction or initiation:  which depends on a protein complex consisting of 
ULK1 (ATG1 homologue), ATG13 and FIP2000 proteins, leading to the 
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formation of the phagophore and is negatively regulated by Mechanistic 
Target of Rapamycin Complex 1 (MTORC1);  
(ii) nucleation:  which is mediated by the Beclin 1 and hVps34/class III 
phosphoinositide 3-kinase (PI3K) complex that produces 
phosphatidylinositol-3-phosphate (PtdIns3P) and recruits various essential 
proteins to the autophagosomes;  
(iii) elongation, which is required for the completion of autophagosomes by 
making use of two ubiquitin-like conjugation systems (Atg12-Atg5 system 
and the LC3/Atg8 system) that results in the covalent binding of 
phosphatidylethanolamine (PE) to the carboxyl-terminal glycine of LC3/Atg8 
protein which is then localized to the autophagosomal membrane;  
(iv) maturation and degradation, which involves fusion of the completed 
autophagosomes with endosomes-lysosomes to form autolysosomes whereby 








Figure 1. Summary of the different stages of the autophagy process in mammalian cells 
(Rubinsztein et al., 2012a). 
  
1.1.3 Regulatory pathways of autophagy 
The class I PI3K-Akt-MTORC1 signaling network is one of the key negative regulators 
of autophagy in mammalian cells. When MTORC1 is activated in the presence of 
nutrients and amino acids, it is able to directly phosphorylate ULK1 and Atg13 to inhibit 
the ULK1-Atg13-FIP200 complex, thus preventing the initiation step of autophagosome 
formation (Hosokawa et al., 2009; Jung et al., 2009; Mizushima, 2010). Under nutrient 
starvation or treatment with chemical inhibitors of MTOR, MTORC1 activity is inhibited, 
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thus releasing the ULK1-Atg13-FIP200 complex from its inhibitory phosphorylation and 
leading to initiation of autophagy in the cells (Jung et al., 2010).   
As an upstream inhibitor of MTORC1 activity, AMP-activated protein kinase (AMPK) 
has been shown to be able to induce autophagy during periods of metabolic stresses 
(Ravikumar et al., 2010b). Apart from its ability to induce autophagy via the inhibition of 
MTORC1 activity (Gwinn et al., 2008; Inoki et al., 2006; Laplante and Sabatini, 2012), 
recent studies have identified other molecular mechanisms by which AMPK can directly 
affect the induction of autophagy. Studies have shown convincingly that under conditions 
of glucose starvation, AMPK is able to directly phosphorylate ULK1 on multiple sites 
leading to its activation and ultimately autophagy induction (Egan et al., 2011; Kim et al., 
2011). Furthermore, AMPK is able to phosphorylate  Beclin-1 that is present in specific 
Vps34 complexes during energy stresses to promote autophagy (Kim et al., 2013). 
Interestingly, there have been other protein kinases that have been described to activate 
autophagy apart from MTORC1 and AMPK described above. One of the protein kinase 
shown to be critical for autophagy induction during nutrient starvation is the c-Jun NH2-
terminal kinase (JNK). JNK signaling pathway plays a critical role in regulation of cell 
fate and is essential for cellular response to stress stimuli (Weston and Davis, 2007). The 
antiapoptotic protein Bcl-2 binds to Beclin-1 during nutrient sufficiency and thus inhibits 
the autophagy induction function of Beclin-1 (Pattingre et al., 2005). Under starvation 
conditions, JNK1 phosphorylates Bcl-2 and prevents its interaction with Beclin-1, thus 
freeing up Beclin-1 to participate in autophagy induction (Wei et al., 2008a; Wei et al., 
2008b). Another protein kinase that has been implicated in autophagy induction is the 
Extracellular Signal-Regulated Kinase (ERK) signalling cascade. It has been shown that 
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the activity of ERK can be activated during amino acid starvation leading to the induction 
of autophagy which is independent or MTORC1 regulation (Pattingre et al., 2003). It was 
established that ERK activation stimulates autophagy by phosphorylation of the G -
interacting protein (GAIP) which leads to hydrolysis of GTP and induction of autophagy 
(Ogier-Denis et al., 2000). More recently, a study has reported that sustained ERK 
activation can lead to the disassembly of both MTORC1 and MTORC2 while enhancing 
Beclin-1 activity and resulting in autophagy induction (Wang et al., 2009). A summary of 
the common signaling pathways regulating autophagy is provided in Figure 2 below 
(Yang and Klionsky, 2010a). 
    




Recent studies on the regulation of autophagy have also uncovered the existence of 
MTORC1-independent regulation of mammalian autophagy. The first such evidence was 
uncovered when it was shown that decreasing the intracellular levels of myo-inositol 
1,4,5-triphosphate (IP3) via pharmacological drugs like lithium which inhibits inositol 
monophosphatase can lead to autophagy induction that is independent of MTORC1 
signaling pathway (Sarkar et al., 2005). It was later shown in a large scale chemical 
screen that L-type Ca
2+
 channel inhibitors, K
+
 ATP channel opener, and Gi signaling 
activators all have the ability to induce autophagy independent of MTORC1 regulation 
(Sarkar and Rubinsztein, 2008). These drugs reveal a novel regulatory pathway for 
autophagy in which cAMP and intracellular levels of Ca
2+
 play a crucial role in 
autophagy induction independent of MTORC1 (Mehrpour et al., 2010; Ravikumar et al., 
2010b). A more detailed study showed that IP3 receptors (IP3R) formed a complex with 
Beclin-1 that was regulated by Bcl-2 (Vicencio et al., 2009). Experiments using genetic 
knockdown or chemical inhibitors of IP3R were able to lead to autophagy induction via 
disruption of the IP3R-Beclin-1 complex that was again independent of MTORC1 
regulation (Vicencio et al., 2009).   
Another group of protein kinases that has been implicated in autophagy induction is the 
Protein Kinase C (PKC) family (Chen et al., 2008; Sakaki and Kaufman, 2008; Sakaki et 
al., 2008). The PKC family consists of serine/threonine protein kinases that are 
categorized into the following 3 classes: classical (containing , β and γ), novel 
(containing δ, η, ε and θ) and atypical (containing ζ, λ and µ). The PKC family was first 
identified as protein kinases that were activated by membrane phospholipids and 
intracellular calcium ions (Ca
2+
) (Newton, 2001; Takai et al., 1979). Subsequently, the 
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PKC family was shown to be intracellular receptors for the tumor promoting phorbol 
esters, making it one of the first kinases shown to be involved in carcinogenesis 
(Castagna et al., 1982; Kikkawa et al., 1983). Further in depth studies then showed that 
the hydrolysis of phosphatidylinositol (4,5)-biphosphate (PIP2) by phospholipases like 
phospholipase C (PLC) to form the second messengers, inositol-1,4,5-triphosphate (InsP3) 
and diacylglycerol (DAG) are required to trigger the release of Ca
2+
 and PKC activation 
(Wymann and Schneiter, 2008). Cellular stresses that affect endoplasmic reticulum (ER) 
homeostasis would disrupt protein folding and activate the unfolded protein response 
(UPR) and autophagy (He and Klionsky, 2009). Amongst the PKC family, PKC-θ has 
been shown to be required for the induction of autophagy under ER stress conditions in a 
Ca
2+
 dependent but MTORC1 independent manner (Sakaki and Kaufman, 2008; Sakaki 
et al., 2008). It was also reported that another member of the PKC family, PKC-δ is 
required for induction of autophagy under acute hypoxic conditions (Chen et al., 2008). A 
recent study has implicated that activation of PKC-δ in the induction of antibacterial 
autophagy (Shahnazari et al., 2010), thus strengthening the importance of PKC family for 
autophagy induction under specific stress stimulus in cells.  
1.1.4 Biological functions of autophagy  
Autophagy has been shown to be an important cellular catabolic process for maintaining 
cellular homeostasis. Basal levels of autophagy are essential for the removal of unfolded 
proteins and damaged organelles in the cytosol of the cells to prevent damages to the cells. 
Autophagy can also be induced during times of nutrient deprivation and cellular stresses 
where it plays a key role as a pro-survival mechanism via recycling of nutrients such as 
amino acids and fatty acids (FAs). The most well-established regulatory pathway of 
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autophagy is the PI3K-Akt-MTORC1 pathway (Mizushima, 2007). The MTORC1 
signaling pathway is the convergent point of signaling pathways originating from growth 
factors like insulin and nutrients such as amino acids, and it has been identified as a key 
negative regulator directly upstream of the ULK1/Atg1 complex (Jung et al., 2009; 
Mizushima, 2010).  During nutrient deprivation, autophagy is induced to degrade cellular 
components and to recycle the nutrients for cell survival. For example, it has been shown 
that activation of autophagy is essential for the survival of newborn mice that were 
deprived of food and nutrients upon birth (Efeyan et al., 2013; Kuma et al., 2004). Recent 
studies have reported the role of autophagy in regulating the breakdown of stored lipids 
in the cells during starvation (Settembre et al., 2013; Singh et al., 2009a) and the details 
will be discussed in the following sections 
Once thought to be a non-selective degradation process, many studies have now shown 
that autophagy can indeed selectively degrade defective and damaged cellular organelles 
to maintain cellular homeostasis. For example, mitophagy is a selective form of 
autophagic process that targets damaged mitochondria for degradation in the cells to 
prevent intracellular accumulation of these damaged mitochondria which leads to 
increase of reactive oxygen species (ROS) and occurrence of DNA damages (Kim et al., 
2007; Kissova et al., 2007; Zhang et al., 2007). Other types of selective autophagy that 
have been identified include pexophagy whereby excessive or damaged paroxysms are 
removed from the cells (Deosaran et al., 2013; Sakai et al., 2006), and reticulophagy 
which is the selective degradation of ER in cells (Bernales et al., 2006). Autophagy is 
known to be important for degradation of protein aggregates which are resistant to the 
ubiquitin-proteasome degradation system (Kirkin et al., 2009). The p62 protein is a 
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selective substrate of autophagy that can interact with LC3 protein and is sequestered into 
the autophagosome for degradation during autophagy (Shvets et al., 2011; Weidberg et al., 
2011). The impairment of autophagy by the deletion of Atg7 in mice can lead to 
formation of poly-ubiquitinated p62 protein aggregates or inclusion bodies which can 
contribute to the pathogenesis of various diseases (Komatsu et al., 2007; Komatsu et al., 
2005; Zatloukal et al., 2002), thus suggesting the importance of autophagy in clearance of 
cytotoxic protein aggregates.  
Apart from being implicated as a major cell survival process, autophagy has also been 
suggested to cause cell death, although this has been the subject of much debate and an 
area of intense research. It has been suggested that autophagic process contributes to cell 
death by a process that has been termed Type II cell death or autophagic cell death 
(Galluzzi et al., 2012), which is characterized by dying cells with increased  number of 
autophagosomes. The widely accepted model for autophagic cell death has come from the 
lower eukaryotes like the Dictyostelium discoideum which is defective in apoptosis, 
based on the observations that  the loss of ATG1 was able to reduce cell death (Kosta et 
al., 2004). Autophagic cell death has been studied extensively in Drosophila 
melanogaster where it was shown that overexpression of loss of function mutants of Atg2 
and Atg18 or knockdown of Atg1 and Atg18 rescued cell death and delayed clearance of 
the midgut section (Denton et al., 2010; Denton et al., 2009). On the other hand, the 
occurrence of autophagic cell death in mammalian systems is more controversial. Indeed, 
there seems to be overwhelming evidence showing that disruption of autophagy process 
does not disrupt cell death in many mouse models. For example, apart from the BECLIN 
1 knockout mice which displayed increased embryonic lethality due to enhanced 
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apoptosis (Yue et al., 2003), no disruption of cell death was observed in the various ATG 
knockout mouse models that have been generated including ATG5 (Kuma et al., 2004; Qu 
et al., 2007) and ATG7 (Komatsu et al., 2005). Most supporting evidence for the pro-cell 
death effect of autophagy has come mainly from in vitro cell culture systems where there 
is the absence of the apoptotic machinery, such as the Bax-/-Bak-/- double knockout 
MEFs. Bax and Bak proteins belong to the pro-apoptotic Bcl-2 family and these double 
knockout MEFs are known to be resistant to apoptotic cell death. When stimulated with 




 double knockout 
MEFs died via autophagic cell death and the cell death could be rescued by knockdown 
of Atg5 or Beclin 1 expression (Shimizu et al., 2004; Shimizu et al., 2010). However, a 
recent report has suggested that autophagy rarely, if ever, serves as an executioner of cell 
death in cells and that most evidence suggest that autophagy is cytoprotective instead 
(Shen et al., 2011). In this study, the authors screened more than 1400 chemical 
compounds possessing anti-tumour capabilities in a panel of cancer cells and found that 
59 compounds were able to cause an increase in autophagic flux. Most importantly, none 
of these compounds identified were able to induce autophagic cell death since inhibition 
of autophagy via the knockdown of Atg5 or Atg7 did not rescue the cancer cells from 
cytotoxic effects of the chemical compounds (Shen et al., 2011). Instead, the authors 
showed convincingly that autophagy inhibition caused an increased rate of cell death in 
the cancer cells treated with these autophagy inducing chemical compounds, thus 
suggesting that autophagy is a cytoprotective mechanism (Shen et al., 2011).  
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1.1.5 Implications of autophagy in human diseases  
Recent studies have also brought into focus the role of autophagy in the development of 
various human diseases like cancer, neurodegenerative diseases and metabolic disorders 
(Meijer and Codogno, 2009; Mizushima et al., 2008). Mouse models with Atg gene 
knockout has been developed and these mouse models have shown that the loss of 
autophagy leads to the development of neurodegenerative conditions like Huntington’s 
disease, Parkinson’s disease and Alzheimer’s disease (Funderburk et al., 2010; Hara et al., 
2006; Komatsu et al., 2006; Sarkar and Rubinsztein, 2008; Yue et al., 2009). For example, 
it is now known that activation of the autophagic process can help to enhance the 
clearance of the huntingtin protein aggregates in Huntington’s disease (Jeong et al., 2009; 
Williams et al., 2008). Mouse models with Atg5 or Atg7 knocked-out specifically in 
neurons have been shown to have excessive accumulation of ubiquitin containing 
inclusion bodies and excessive neuronal cell death (Hara et al., 2006; Komatsu et al., 
2006), suggesting conclusively that removal of cytotoxic protein aggregates from the 
neurons requires functional autophagy (Hara et al., 2006; Komatsu et al., 2006).  
Furthermore, autophagy has been implicated in tumorigenesis and cancer development as 
well (Apel et al., 2009; Chen and Debnath, 2010; Levine and Kroemer, 2008; Mathew et 
al., 2007a). Earlier studies had reported an increase in the incidence of tumorigenesis in 
mice upon the allelic loss of Beclin-1, while this phenotype could be reversed by over-
expression of Beclin-1 (Liang et al., 1999; Yue et al., 2003). Furthermore, other 
components that make up the Beclin-1/Vps34 complex essential for the autophagic 
process like ultraviolet irradiation resistance-associated gene (UVRAG), Ambra1 and 
Bif-1 have been shown to have tumour suppressive functions as loss of these proteins and 
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autophagy activity led to tumour development (Fimia et al., 2007; Takahashi et al., 2007). 
However, the mechanisms behind the tumour suppressive function of autophagy are still 
largely unknown. One of the commonly suggested mechanism is that autophagy in cells 
is able to prevent the accumulation of excessive ROS in the cells and thus limit DNA 
damage and genome instability that could lead to tumour initiating genetic mutations. 
Several studies reported that autophagy was critical for the removal of damaged 
mitochondria and limiting the production of ROS, subsequently led to the suppression of 
tumorigenesis (Karantza-Wadsworth et al., 2007; Mathew et al., 2007b).  
In addition, autophagy has also been shown to be important for the elimination of 
invading pathogens such as bacteria, parasites and viruses (Levine and Deretic, 2007; 
Shahnazari et al., 2010). Autophagy has been shown to promote the innate and adaptive 
immunity responses of infected cells. For example, it has been reported that autophagy is 
important in promoting MHC class II presentation of cytosolic antigens to boost the 
adaptive immunity response as the pharmacological and genetic inhibition of autophagy 
has been shown to decrease the efficiency of MHC class II presentation (Nimmerjahn et 
al., 2003; Paludan et al., 2005). Autophagy has also been implicated in many other human 
diseases including muscle myopathies, ageing, liver and cardiovascular diseases which 
have been extensively reviewed elsewhere (Mizushima and Komatsu, 2011; Mizushima 
et al., 2008; Ravikumar et al., 2010b) and will not be discussed further here. 
1.2 Lipids and autophagy 
1.2.1 Introduction to lipids 
Lipids make up a major class of macromolecules that are absolutely essential for cell 
survival and growth. This class of macromolecules is required for a wide variety of 
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cellular structures and biological functions (van Meer et al., 2008; Wymann and 
Schneiter, 2008). The different types of lipids that have been identified so far are shown 
in Figure 3 (Roberts et al., 2008). The most well-established cellular function of lipids is 
their role in the formation of the phospholipid bilayer of cell membrane or cellular 
organelles that acts as the barrier to limit permeability of different molecules into cells 
(Dowhan, 1997; van Meer et al., 2008). This compartmentalization of intracellular 
organelles is important for specific cellular processes to take place. Another well-
established function of lipids is their ability to act as signaling molecules during signal 
transduction in cells (Dowhan, 1997; Lemmon, 2008; van Meer et al., 2008; Wymann 
and Schneiter, 2008). For example, the rapid production of PIP3 from PIP2 that is 
modulated by Class I PI3K during activation of receptor tyrosine kinases is essential for 
signal transduction for the PI3K-Akt-MTOR signaling pathway. As mentioned earlier, 
PLC mediates the production of  InsP3 and DAG through the hydrolysis of PIP2 at the 
plasma membrane, leading to Ca
2+
 release from intracellular stores and activation of PKC 





Figure 3: Summary of the different groups of lipid species in cells (Roberts et al., 2008).   
 
Another important function of lipids is to act as storage of excess FAs in cells in the form 
of lipid droplets (LD) in the cytoplasm of the cells (Martin and Parton, 2006; Thiele and 
Spandl, 2008). The core of LD consists of neutral lipids like triacylglycerol (TAG) and 
cholesterol ester (CE) which are surrounded by a monolayer of phospholipid membrane 
and LD associated proteins (Coleman and Mashek, 2011; Ducharme and Bickel, 2008; 
Martin and Parton, 2006). This lipid store can act as a reserve of energy store for the cells 
to access during energy deprivation and the stored lipids can be tapped for synthesis of 
other important lipid molecules (Ducharme and Bickel, 2008).     
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1.2.2 Regulatory roles of lipids in autophagy 
Lipids are intimately linked to the various steps of the autophagic process and the 
presence of various lipid species are essential for autophagy to be carried out in the cells. 
For example, the availability of lipids can influence the formation of the autophagosomal 
membrane which is absolutely required for the sequestration of autophagic targets in the 
cytosol to finally form the completed autophagosome structure. A few examples of lipid 
species which are important for autophagy to occur includes PtdIns3P which is the 
product of the Class III PI3K, Vps34. PE on the other hand is required for conjugation to 
LC3 protein. Apart from its involvement in the autophagic process, many studies have 
shown that lipids species like sphingolipids can also have a regulatory effect on the 
autophagic process by directly affecting signalling pathways upstream of autophagy. The 
detailed regulatory roles of various lipids on autophagy are discussed in further details in 
the following sections. 
1.2.2.1 Lipid source of autophagosomal membrane 
The main focus of research on the role of lipids in autophagy has largely been on their 
involvement in the process of the nucleation and formation of the double membrane 
bound autophagosome. Many studies have suggested that lipids from several sources 
contribute to autophagosome formation (Hamasaki et al., 2013b; Mari et al., 2011; 
Rubinsztein et al., 2012b) but the exact origin of the autophagosomal membrane remains 
unknown. One early model proposed that autophagosomal membrane could be formed by 
de novo lipid synthesis on site, based on the fact that the autophagosomal membrane 
lacked transmembrane proteins and other cytoplasmic organelle protein marker 
(Stromhaug et al., 1998; Tooze and Yoshimori, 2010). However subsequent studies have 
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suggested that the autophagosomal membrane most probably arise from pre-existing 
organelles in the cells (Tooze and Yoshimori, 2010). Many independent studies have 
since presented evidences suggesting the ER, mitochondria, plasma membrane or Golgi 
apparatus as possible sites of origin of the autophagosome membrane (Hailey et al., 2010; 
Hayashi-Nishino et al., 2009; Ravikumar et al., 2010a; Yla-Anttila et al., 2009; Young et 
al., 2006). However, recent studies have provided evidence to suggest a new model 
whereby both the ER and mitochondria contribute to autophagosome membrane synthesis 
(Hamasaki et al., 2013a; Hamasaki et al., 2013b). In that study, the authors showed that 
under starvation conditions, the pre-autophagosome/autophagosome marker Atg14L 
localizes to the ER-mitochondria contact site known as mitochondria-associated ER 
membrane (MAM) and disruption of MAM leads to defective autophagosome formation 
(Hamasaki et al., 2013a; Hamasaki et al., 2013b). The results from these studies will 
certainly help to explain previous results whereby either the ER or mitochondria was 
identified as the source of autophagosome membrane. However, more work will need to 
be conducted to investigate if autophagosome formation independent of the MAM can be 
observed in cells.    
1.2.2.2 Role of PtdIns3P in autophagosome nucleation  
It is now known that formation of specific lipid species like PtdIns3P is required for the 
nucleation step of autophagosome formation (Nakatogawa et al., 2009; Yang and 
Klionsky, 2010b). The Class III PI3K, Vps34 is well conserved from yeast to mammalian  
and is required for the formation of a complex that consists of other protein components 
including Atg14L, Beclin 1 and Vps15 (Itakura et al., 2008; Longatti and Tooze, 2009; 
Zhong et al., 2009). In mammalian cells, this particular complex has been reported to be 
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localized to a structure at the ER termed omegasome during starvation-induced 
autophagy (Axe et al., 2008). This complex is essential for autophagy to occur and the 
only known substrate of Vps34 is the building block of inositol lipid, 
phosphatidylinositol (PtdIns), which is phosphorylated to form PtdIns3P 
(Vanhaesebroeck et al., 2001). PtdIns3P is one of the major lipid constituent of 
autophagosome in yeast (Obara et al., 2008) and has been shown to be able to bind to and 
recruit proteins containing the FYVE or PH domains (Vanhaesebroeck et al., 2001; 
Yoshimori and Noda, 2008) to the autophagosomal membrane to participate in the 
subsequent membrane curvature, fusion and degradation of the autophagosome. 
Interestingly it has been established that the activation of Vps34 is actually dependent on 
the presence of amino acids and starvation actually causes a decrease in the lipid kinase 
activity of the cells leading to a decrease in the total intracellular levels of PtdIns3P 
(Byfield et al., 2005; Gulati et al., 2008).  However, a recent study has identified that 
Beclin-1 protein that is present in a particular Vps34 complex consisting of Atg14L, 
Beclin-1 and Vps34 is specifically phosphorylated by ULK1 upon amino acid starvation 
leading to the activation of the lipid kinase activity of Vps34 and increased PtdIns3P 
production at autophagosomal membrane (Russell et al., 2013). Results from this study 
confirm that only Vps34 present in specific complexes that are recruited to the 
phagophore via Atg14L upon autophagy induction can be activated to produce PtdIns3P.  
Apart from Vps34, Jumpy (MTMR14) and MTMR3 are 2 PtdIns3P phosphatases that 
have been shown to inhibit autophagy activity by regulating PtdIns3P turnover as well. 
The increase in activity of these lipid phosphatases dephosphorylate and decrease the 
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overall PtdIns3P levels in the cells leading to a decrease in autophagic activity mainly in 
nutrient rich conditions (Taguchi-Atarashi et al., 2010; Vergne et al., 2009).  
 
1.2.2.3 Role of PE in autophagosome expansion  
Another type of lipid involved in autophagosome formation and elongation as mentioned 
earlier is PE. PE is conjugated to Atg8/LC3 protein during autophagy by an ubiquitin-like 
system involving Atg7 and Atg3 which are E1 and E2 enzymes, respectively, in the 
ubiquitylation reaction to form LC3-PE (Ichimura et al., 2000). This lipidated form of 
LC3 is found on both sides of the isolation membrane and the autophagosome membrane. 
LC3-PE present within the autophagosomal lumen will eventually be degraded after 
fusing with the lysosomes while those at the outer autophagosome membrane surface can 
be recycled for further use (Kirisako et al., 2000; Nakatogawa et al., 2009). This lipidated 
form of LC3 is essential for the expansion of the autophagosomal membrane after 
nucleation and loss of LC3 expression has been shown to lead to accumulation of 
unclosed isolation membrane in cells (Noda et al., 2009; Xie et al., 2008). Furthermore, 
results from in vitro experiments conducted with purified protein components and 
liposomes containing PE have suggested that this lipidated form of LC3-PE mediates the 
membrane tethering and hemifusion of the autophagosome, a process presumably 
required for the fusion with lysosomes (Nakatogawa et al., 2007).   
1.2.2.4 Role of sphingolipids in autophagy 
Apart from investigating the effects of autophagy on lipid metabolism, many studies have 
tried to look at how different types of lipid species are able to regulate autophagic activity. 
Perhaps the most well studied lipid species in this aspect are the sphingolipids. 
19 
 
Sphingolipids are a class of lipids that are major components of lipid membrane and 
certain species can be produced as second messengers during signal transduction in cells. 
They have been shown to affect biological processes like cell growth, cell death, 
tumorigenesis, stress responses and autophagy (Holland and Summers, 2008; Kihara et 
al., 2007; Mehrpour et al., 2010; Ravikumar et al., 2010b; Zheng et al., 2006). The main 
species of sphingolipids that have been shown to regulate autophagic activity are 
sphingosine-1-phosphate (S1P) and ceramide. While ceramide in the cells can be 
obtained via de novo synthesis, S1P in the cells can only be synthesized via two 
sequential steps: first formation of sphingosine from ceramide via a deacylation process, 
and then sphingosine is phosphorylated to give rise to S1P (Spiegel and Milstien, 2003). 
S1P has been shown to promote cell growth and survival while in contrast, ceramide is a 
known inducer of cell death. Therefore, tight regulation of the ratio of these two lipid 
metabolites has been referred to as the ‘sphingolipid rheostat’ in cells and is crucial in 
determining the cell fate (Cuvillier et al., 1996; Hannun and Obeid, 2008). 
Overexpression of sphingosine kinase-1 (SK1), which is responsible for producing S1P 
leads to induction of autophagy via inhibition of MTORC1 signaling without inhibiting 
the upstream PI3K-Akt signaling pathway (Lavieu et al., 2006). More importantly, SK1 
activity was also shown to be elevated during nutrient starvation and knocking down SK1 
abrogated starvation-induced autophagy and resulted in increased cell death (Lavieu et al., 
2006). Furthermore, knockdown of sphingosine phosphate phosphohydrolase-1 which is 
responsible for dephosphorylating S1P resulted in autophagy induction due to increased 
intracellular S1P levels (Lepine et al., 2011). Autophagy induction in this context was 
independent of MTORC1 regulation but instead dependent on ER stress signalling, based 
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on the observations that  autophagy induction could be inhibited by silencing of proteins 
involved in propagating the unfolded protein response (UPR) (Lepine et al., 2011). On 
the other hand, addition of exogenous short chain C2-ceramide was able to cause 
increased synthesis and accumulation of long-chain ceramide in cancer cells, leading to 
autophagy induction due to inhibition of Akt activation and subsequent MTORC1 activity 
(Scarlatti et al., 2004). Inhibition of Akt activity was later suggested to be due to the 
down regulation of amino acid transporters from the cell surface upon ceramide treatment 
(Guenther et al., 2008). There was a concomitant increase of Beclin-1 levels in these cells 
treated with C2-ceramide (Guenther et al., 2008) and similar observations were observed 
in cells treated with tamoxifen which causes increased production of ceramide in cells 
(Scarlatti et al., 2004). It was also suggested that ceramide accumulation could lead to 
JNK activation which phosphorylates Bcl-2 and relieves its inhibitory effect on 
autophagy by causing the phorphorylated Bcl-2 to dissociate from Beclin-1 (Pattingre et 
al., 2009). A recent study has implicated mitochondrial localized long chain C18-
ceramide produced by ceramide synthase 1 (CerS1) to be involved in mediating 
autophagic cell death (Sentelle et al., 2012). The authors showed that mitochondrial 
localized C18-ceramide, through direct binding to lipidated form of LC3 could lead to 
mitophagy and ultimately cell death due to disruption of mitochondria and energy 
homeostasis in the cells (Sentelle et al., 2012). Thus more studies are needed to 
understand how cells regulate the internal ‘sphingolipid rheostat’ in response to different 
types of stresses and the role of autophagy in response to changing ceramide and S1P 
levels in the cells.  
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1.2.2.5 Role of cholesterol in autophagy 
Autophagy has been shown to control intracellular cholesterol levels via regulation of 
cholesterol efflux in macrophages (Ouimet et al., 2011).  Interestingly, cholesterol has 
also been shown in different studies to play contrasting roles in the regulation of the 
autophagic process. For example, depletion of cholesterol with different chemical 
inhibitors like methyl-β-cyclodextrin (MBCD)  or depletion of lipoprotein from culture 
medium was first shown to be able to induce autophagy in multiple cell lines (Cheng et 
al., 2006). Furthermore, the authors showed that depletion of cholesterol led to the 
inhibition of MTOR activity and activation of autophagy. Interestingly, disruption of lipid 
raft microdomains by cholesterol depletion using MBCD has already been shown to 
induce chaperone mediated autophagy (CMA) (Kaushik et al., 2006), while increasing 
cholesterol content in lysosomes will lead to inhibition of CMA (Kaushik et al., 2006; 
Rodriguez-Navarro et al., 2012). These studies suggest that autophagy induced by 
cholesterol depletion could be directly associated with the depletion of lipid raft 
microdomains in cells. On the other hand, there are studies suggesting that depletion of 
cholesterol levels will lead to the inhibition of autophagic activity. It was shown in an in 
vitro assay model that autophagic process can be inhibited by specifically depleting 
cholesterol from isolated autophagosomes and lysosomes, probably via suppression of the 
formation of autolysosomes (Koga et al., 2010). The authors further presented evidence 
showing that lysosomes and autophagosomes isolated from mice that were exposed to 
High Fat Diet (HFD) had decreased levels of cholesterol on their respective membranes, 
thus supporting their earlier findings that autophagy was inhibited in mice exposed to 
chronic HFD (Koga et al., 2010; Singh et al., 2009a). On the other hand, disruption of 
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cholesterol trafficking has been implicated in autophagy induction in the central nervous 
system of mice suffering from a neurodegenerative disease, Niemann-Pick Type C (NPC) 
(Liao et al., 2007; Pacheco et al., 2007; Pacheco and Lieberman, 2007). NPC is a type of 
lipid storage disorder characterized by defects in sphingolipids and cholesterol trafficking 
due to mutations in NPC1 and NPC2, leading to accumulation of cholesterol in the 
neurons (Liao et al., 2007; Pacheco et al., 2007; Pacheco and Lieberman, 2007). The 
studies showed that NPC1 deficiency led to accumulation of intracellular cholesterol, 
which through an unknown mechanism resulted in increased expression of Beclin-1 in 
these NPC1 deficient cells. The increase in Beclin-1 levels in the cells was shown to be 
responsible for the increase in basal autophagic activity in the cells which was 
independent of MTORC1 inhibition (Pacheco et al., 2007; Pacheco and Lieberman, 2007).  
1.2.2.6 Role of DAG in autophagy 
Apart from cholesterol, another neutral lipid that has been described to have an effect on 
the regulation of autophagic activity is DAG. DAG species are important second 
messengers in cells because of their ability to activate protein kinases such as the PKC 
family as mentioned earlier (Newton, 2001). DAG has recently been shown to be 
involved in the induction of autophagy caused by various types of cellular stresses. It was 
demonstrated that DAG production is essential for effective antibacterial autophagy to be 
carried out during infection of the cells by Salmonella typhimurium and that DAG was 
found to be co-localized with the bacterial containing phagosomes at the very early stages 
of autophagy induction (Shahnazari et al., 2010). The authors went on to propose that the 
source of DAG came from the sequential breakdown of phosphatidylcholine (PC) into 
phosphatidic acid (PhA) by phospholipase D1 (PLD1) followed by dephosphorylation of 
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PhA to DAG by phosphatidic acid phosphatase (PAP) (Shahnazari et al., 2010). 
Furthermore, they further showed that DAG was able to activate PKCδ, an isoform 
belonging to the novel PKC family. PKCδ activation resulted in activation of JNK which 
in turn phosphorylates Bcl-2 protein to cause it to dissociate from its inhibitory 
interaction with Beclin-1, resulting in the activation of autophagy (Shahnazari et al., 2010; 
Wei et al., 2008a). It has been well established that the activation of classical PKC family 
is not only Ca
2+
-dependent, but also requires both DAG and phosphotidylserine (PS); 
while activation of the novel PKC family is Ca
2+
-independent but dependent on DAG and 
PS and finally, activation of the atypical family of PKC is independent of either Ca
2+
 or 
DAG (Newton, 2001). As mentioned earlier, novel PKC members like PKC-θ (Sakaki 
and Kaufman, 2008; Sakaki et al., 2008) and PKC-δ (Chen et al., 2008) are required for 
autophagy induction caused by stress factors such as  hypoxia and ER stress. On the other 
hand, there is report showing the importance of PLD1 activity in autophagy induction 
(Dall'Armi et al., 2010). The authors showed that during nutrient starvation, PLD1 was 
found to localize to outer membrane of autophagosome-like structure and an increase in 
its catalytic activity was observed resulting in a subsequent increase in the PhA levels in 
the cell (Dall'Armi et al., 2010). PhA has also been shown to be a direct binding partner 
of MTOR and is essential for the stability and activity of MTORC1 and MTORC2 (Fang 
et al., 2001; Foster, 2013; Toschi et al., 2009). In particular, MTORC1 is sensitive to 
changes in PhA levels in cells and PLD1 is localized on lysosomal membrane in response 
to amino acids and could increase the production of PhA to activate MTORC1 (Yoon et 
al., 2011). Therefore, more work will have to be done to investigate whether the increase 
in PhA levels will ultimately lead to an increase in DAG levels as well as to determine 
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the downstream targets of PKC to elucidate how the PLD1-PhA-DAG-PKC signaling 
pathway in the control of autophagy. It will also be important to investigate whether other 
sources of PhA and DAG can contribute to autophagy induction. 
1.2.2.7 Role of Free Fatty Acids and lipotoxicity in Autophagy 
Free fatty acids (FFAs) are the basic building blocks of lipids and have been implicated in 
the cause of metabolic diseases such as diabetes. FAs are aliphatic monocarboxylic acids 
and most natural FAs have chain lengths between C4 and C22 (Fahy et al., 2005). There 
are generally 2 major classes of FAs, namely the saturated and unsaturated fatty acids. 
Saturated FAs (SFAs) contain no double bonds in their aliphatic carbon chains while 
unsaturated FAs contain single or multiple carbon-carbon double bonds forming 
monounsaturated (MUFA) or polyunsaturated (PUFA) FAs, respectively. FFAs in the 
cytosol of cells can be converted to fatty acyl-CoA by fatty acyl-CoA synthetase (FACS) 
and then be utilized as precursors for synthesis of other lipid species. Furthermore, the 
fatty acyl-CoA chains are an important energy source for cells as they can be transported 
into the mitochondria and then broken up via a multi-step process called β-oxidation to 
produce acetyl-CoA that is ultimately used to generate ATP (Li et al., 2010; Lopaschuk et 
al., 2010).  
When there is an excess supply of FFAs either from the breakdown of fats in the diet or 
from increased de novo lipogenesis, the excess FFAs will be converted to TAG and 
stored as LD in the cytoplasm of the cells (Martin and Parton, 2006; Thiele and Spandl, 
2008). Storage of FFAs as LDs is important because LDs not only act as a store of energy 
source but also sequesters the toxic FFAs in an inert form within cells. Normally, 
adipocytes are the main cell type in the body that can store large amounts of lipids, while 
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non-adipocytes like the hepatocytes, cardiac myocytes, pancreatic β cells and skeletal 
muscles can also store lipids, albeit to a much smaller extent (Brookheart et al., 2009; 
Schaffer, 2003). High levels of lipid accumulate intracellularly due to an imbalance 
between the levels of FFA import/synthesis and utilization. Excess fatty acids are 
normally esterified and stored as LD that can be utilized when broken down by cellular 
lipases. In cases where there are elevated FFAs in the body, lipid storage within the non-
adipocytes might exceed the limit and the excess FFAs present in the cells thus causes 
lipotoxicity. Lipotoxicity refers to excessive accumulation of lipid in non-adipose 
tissues/cells which ultimately leads to loss of cellular functions and cell death 
(Brookheart et al., 2009; Unger, 2002). This phenomenon has been shown in many 
studies where the excessive levels of serum FFA leads to, for example, dysfunction and 
ultimately the death of pancreatic β cells in diabetes and obesity (Cunha et al., 2008; 
Shimabukuro et al., 1998b), development of insulin resistance in skeletal muscle (Kim et 
al., 2000) and death of mouse myocardiocytes that could lead to heart failure (Chiu et al., 
2001). As a result, lipotoxicity has been hypothesized to be one of the underlying causes 
of diseases associated with excess lipid accumulation in the body, such as cardiac 
diseases, obesity and diabetes (Brookheart et al., 2009; Chavez and Summers, 2010; 
Eckel et al., 2005). Furthermore, the lipid induced programmed cell death caused by 
lipotoxicity in the cells has been termed lipoapoptosis as cells dying from lipotoxicity 
actually undergo via the apoptotic machinery (Shimabukuro et al., 1998a; Unger, 2003; 
Unger and Orci, 2002). Interestingly, a recent study has shown that cells under stress 




One of the major areas of active research regarding lipotoxicity is focused on elucidating 
the group of lipid metabolites responsible for the toxicity. It is known that the long chain 
saturated fatty acids are generally more toxic to cells than the long chain unsaturated fatty 
acids and the secondary lipid metabolites that are synthesized from the saturated FFAs 
are important for inducing cell death (Cunha et al., 2008; Listenberger et al., 2003; 
Listenberger et al., 2001; Maedler et al., 2001; Malhi et al., 2006; Schaffer, 2003). 
Palmitic acid (16C:0, PA) and oleic acid (18C:1, OA) are the two most common dietary 
saturated and monounsaturated FA found in the body, respectively, and thus have been 
the most widely studied FA species for lipotoxicity. Dysfunction and ultimately cell death 
of pancreatic islets brought about by lipotoxicity in different mouse models of obesity are 
known to lead to the development of type 2 diabetes (T2D) (Lupi et al., 2002; Unger and 
Zhou, 2001). Culturing of human or rat pancreatic islets in medium containing PA 
resulted in reduced cell proliferation and increase in cell death, while treatment with 
unsaturated FA like palmitoleic acid (C16:1) or OA did not have any major detrimental 
effects on cell growth (Maedler et al., 2003; Maedler et al., 2001). PA is an essential 
precursor for the generation of ceramide in cells. Therefore, the authors went on to show 
that treatment with a ceramide analog, C2-ceramide had similar effects on cell death seen 
in PA treatment, suggesting that metabolism of PA into ceramide species could be the 
reason for PA-mediated lipotoxicity (Maedler et al., 2003; Maedler et al., 2001). Another 
study has also reported that apoptosis was induced in the Chinese hamster ovary (CHO) 
cells treated with PA but not OA (Listenberger et al., 2001). Moreover, inhibition of de 
novo ceramide synthesis either via chemical or genetic means did not rescue PA-induced 
cell death in CHO cells. Instead, PA-mediated cell death could be blocked by the addition 
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of ROS scavengers, suggesting that cell death was mediated by the generation of ROS 
upon PA treatment (Listenberger et al., 2001).  
Interestingly, lipotoxicity studies in different tissues like pancreatic islets and rat 
myocytes have shown that co-treatment with both PA and OA was able to significantly 
prevent loss of cell viability that was seen with PA treatment alone (de Vries et al., 1997; 
Maedler et al., 2003). This observation was confirmed in another study using CHO cells 
in which the authors went on further to show that OA was taken up and converted to 
TAG to be stored as the non-toxic LDs whereas PA was preferentially converted to the 
cytotoxic ceramide (Listenberger et al., 2003). Furthermore, treatment of cells 
concurrently with PA and OA resulted in the channelling of PA species into TAG 
formation, thus preventing PA-induced cell death (Listenberger et al., 2003). To 
investigate the importance of TAG storage upon lipotoxic stress, the authors made use of 
Diacylglycerol Acyltransferase 1 (DGAT1) knock-out mouse embryonic fibroblasts 
(MEFs) which could not produce TAG as this enzyme is required for the final step of 
TAG synthesis from DAG. Indeed, OA treatment in the Dgat1
-/-
 MEFs did not lead to 
accumulation of TAG but induction of cell death to a similar extent seen in PA treatment 
alone (Listenberger et al., 2003). These studies have suggested that the differences in 
lipotoxic effects of saturated and unsaturated FAs are most probably due to the different 
lipid metabolites which the individual lipid species are channelled into.  
Based on the known effects of FFAs in inducing various cellular stresses such as 
oxidative stress and ER stress which are also known to be involved in regulation of 
autophagy (Cunha et al., 2008; Listenberger et al., 2001; Malhi et al., 2006; Schaffer, 
2003), many studies have thus been carried out to investigate whether FFAs can regulate 
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the autophagic pathway in a positive or negative way. However, currently there is no 
agreement as to whether FFAs are able to induce or inhibit autophagic activity in the 
various tissues and systems. A few studies using pancreatic β cells have shown that FFAs 
treatment is indeed able to induce autophagy (Choi et al., 2009; Ebato et al., 2008; 
Komiya et al., 2010; Martino et al., 2012). PA and OA were both shown to be able to 
induce an increase in autophagic flux in pancreatic β cell line and autophagy was 
identified to play a role in the maintenance of normal islet morphology and function like 
insulin secretion, especially in mice given HFD (Ebato et al., 2008). 
 
Conversely, loss of 
autophagic activity in the islets led to development of insulin resistant state and 
subsequently loss of pancreatic cells function in the mice, thus highlighting the 
importance of autophagy in response to lipotoxic stresses (Ebato et al., 2008). These 
results were also supported by other groups showing that PA could activate autophagy in 
pancreatic β cells and activation of autophagy played an important role for the cell 
survival upon lipotoxic stresses (Choi et al., 2009; Martino et al., 2012). Furthermore, the 
double stranded RNA-dependent protein kinase (PRK)-JNK signaling pathway was 
subsequently shown to be required for the activation of autophagy in PA-treated 
pancreatic β cells (Komiya et al., 2010). This result was  confirmed recently in a study 
showing that PA and other saturated FAs was able to inhibit STAT3 which leads to 
activation of PKR-eIF2  signaling pathway and thus activation of autophagy in numerous 
of cancer cell lines tested (Shen et al., 2012). However, although JNK signaling pathway 
was also activated downstream of PKR, the authors did not pursue whether JNK 




On the contrary, FFAs treatments have been shown to inhibit autophagic process as well. 
For example, exposure of pancreatic β cells to PA or OA for up to 22 hours resulted in 
inhibition of autophagy due to the inhibition of the autophagosome-lysosome fusion and 
inhibition of the hydrolase activity (Las et al., 2011). Specifically, they found that PA or 
OA treatment could result in mitochondria damage, leading to decreased ATP production 
and ultimately affecting lysosomal acidification due to decreased function of the V-
ATPase pump (Las et al., 2011). However, results from another study in cultured and 
primary hepatocytes concluded that OA was able to induce autophagy while PA had an 
inhibitory effect on autophagy (Mei et al., 2011). Activation of autophagy by OA was 
found to be independent of MTOR regulation and attributed to the generation of ROS 
(Mei et al., 2011). Furthermore, the authors showed that PA could induce apoptosis in 
hepatocytes and at the same time inhibited autophagy by activating caspase-mediated 
cleavage of Beclin-1 (Mei et al., 2011). Interestingly, it was shown in an earlier study that 
OA treatment had no effect on the formation of autophagosomes in hepatocytes but 
inhibited lysosomal degradation of autophagic substrates (Singh et al., 2009a).  
1.2.3 Autophagy regulates lipid metabolism 
As discussed earlier, LDs containing TAG can be broken down by cells into FFAs for 
cellular functions including energy production in a process known as lipolysis (Finn and 
Dice, 2006; Zechner et al., 2005). Lipolysis was previously thought to be dependent only 
on lipases that were present in the cytosol of the cells (Finn and Dice, 2006; Zechner et 
al., 2005). However, recent studies have demonstrated that autophagy can regulate lipid 
metabolism in cells by participating in the breakdown of intracellular lipid droplet stores 
into FFAs that can be fed into the mitochondria for β-oxidation to maintain cellular 
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energy homeostasis (Liu and Czaja, 2013; Singh et al., 2009a). The breakdown of LDs by 
autophagy (termed lipophagy)  was suggested to be upregulated during nutrient 
deprivation or when the cells were exposed to extra-cellular lipid stimulus like fatty acids 
or cholesterol (Singh et al., 2009a). Furthermore, in vivo studies with a mouse model 
deficient in autophagy in the liver also displayed increases in the number and size of LDs 
in the hepatocytes together with increased levels of TAG and cholesterol contents (Singh 
et al., 2009a). More importantly, the study reported that chronic exposure of the mice to 
high fat diet (HFD) containing high levels of fatty acids could ultimately lead to 
inhibition of autophagy and lipophagy (Singh et al., 2009a). The importance of lipophagy 
as an event upstream of fatty acid oxidation in mice during starvation has been 
demonstrated in a recent report (Settembre et al., 2013). The transcription factor EB 
(TFEB) was previously identified as a master regulator of lysosomal biogenesis and 
autophagy (Sardiello et al., 2009; Settembre et al., 2011). The same group reported that 
TFEB is induced during starvation and activates lipid catabolism by inducing both 
lipophagy and expression of peroxisome proliferator-activated receptor coactivator 1  
(Ppargc1 ) and peroxisome proliferator-activated receptor  (Ppar ) (Settembre et al., 
2013). More importantly, the authors also demonstrated that breakdown of LDs by 
lipophagy is essential for subsequent processes like fatty acid β-oxidation in the 
mitochondria. Furthermore, HFD-induced obesity in the mice was prevented by the 
overexpression of TFEB which culminates in elevated levels of lipid catabolism 
(Settembre et al., 2013).  
There has been other studies that suggest that functional autophagy in hepatocytes can 
help to dampen ER stress and maintain normal insulin sensitivity in mouse models of 
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obesity (Yang et al., 2010). The loss of autophagy subsequently led to elevated ER stress 
and disruption of systemic glucose tolerance (Yang et al., 2010). These results strongly 
suggest that lipophagy is essential for regulation of lipid storage in the cells and 
disruption of autophagy contributes to the development of pathological conditions such as 
liver steatohepatitis. Apart from the liver, it has been reported that upon exposure of 
macrophages to oxidized lipoproteins (LDL), autophagy is upregulated to degrade CEs 
within the LDs into free cholesterol for efflux and transport to the liver. (Ouimet et al., 
2011). Subsequently, the loss of autophagic activity in the macrophages led to 
accumulation of cholesterol within the cells (Ouimet et al., 2011). Separate studies from 
other groups have instead concluded that autophagy is actually essential for the normal 
development of adipocytes during adipogenesis (Singh et al., 2009b; Zhang et al., 2009). 
By utilizing mice with atg7 knocked out in the adipocytes, it was demonstrated that the 
loss of autophagy led to lean mice with reduction in accumulation of adipose tissue. 
Specifically, in the autophagy deficient mouse there was a major reduction in the 
formation of white adipose tissue with a concomitant increase in brown adipose tissue 
(Singh et al., 2009b; Zhang et al., 2009). Furthermore, these mice possessed enhanced 
levels of insulin sensitivity and were also resistant to HFD-induced obesity (Singh et al., 
2009b; Zhang et al., 2009). Thus results from these studies highlight that the role of 
autophagy might be tissue and cell-type specific.  
1.4 MTORC1 and De Novo Lipogenesis  
1.4.1 MTORC1 Signaling pathway 
The MTOR signaling network is responsible for integrating various nutritional signals to 
regulate cell growth and proliferation by activating or inhibiting a whole range of 
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anabolic and catabolic processes that helps to maintain cellular metabolic homeostasis. 
The MTOR protein is a serine/threonine kinase that makes up the catalytic subunit of 2 
distinct complexes in mammalian cells named MTOR complex 1 (MTORC1) and MTOR 
complex 2 (MTORC2). These two distinct protein complexes share similar protein 
components in containing the catalytic subunit MTOR, mammalian lethal with sec-13 
protein 8 (mLST8), DEP domain containing MTOR interacting protein (DEPTOR) and 
the Tit1/Tel2 complex (Laplante and Sabatini, 2012). Protein components uniquely found 
in MTORC1 include the regulatory-associated protein of MTOR (Raptor) and proline-
rich Akt substrate 40kDA (PRAS40), while rapamycin-insensitive companion of MTOR 
(Rictor) and mammalian stress activated map kinase interacting protein 1 (Sin-1) and 
protein observed with Rictor 1 and 2 (protor1/2)  are specifically found in MTORC2 
(Bhaskar and Hay, 2007). Both complexes not only differ in their protein components, 
but also differ in their regulatory mechanisms and biological functions.  Many studies 
have now shown that MTORC1 is the key sensor and convergent point of nutrients, 
amino acids, growth factors, energy and stress in the cells (Laplante and Sabatini, 2012; 
Zoncu et al., 2011b).  In the presence or absence of these signals, MTORC1 regulates 
major cellular processes like protein and lipid synthesis, mitochondrial biogenesis and 
autophagy (Jewell and Guan, 2013; Laplante and Sabatini, 2012; Yuan et al., 2013). 
MTORC1 is known to be activated by upstream signals originating from growth factors 
and nutrients including amino acids and glucose. When growth factors such as insulin 
binds to its insulin receptor substrate-1 (IRS-1), it triggers the recruitment and activation 
of the PI3K which subsequently phosphorylates and converts phosphatidylinositol (4,5)-
biphosphate (PIP2) to phosphatidylinositol (3,4,5)-triphosphate (PIP3) (Andjelkovic et al., 
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1997; Bhaskar and Hay, 2007; Jewell and Guan, 2013). Akt is then recruited to the 
plasma membrane by PIP3 and activated subsequently through phosphorylation by 
phosphoinositide-dependent kinase-1 (PDK1) at T308 (Alessi et al., 1997) and by 
MTORC2 at S473 (Sarbassov et al., 2005). The fully activated Akt protein then 
phosphorylates and inhibits the Tuberous sclerosis complex 2 (TSC2). The TSC1-TSC2 
complex acts as a GTPase-activating protein (GAP) in cells (Hay and Sonenberg, 2004). 
A recent study has further identified TBC1D7 as a new and essential component of the 
TSC1-TSC2 complex by helping to enhance the interaction between TSC1 and TSC2 and 
its GAP activity (Dibble et al., 2012). The physiological role of the TSC1-TSC2 complex 
in cells was first elucidated in studies using Drosophilla where loss of functional TSC1 
and TSC2 proteins resulted in uncontrolled increase in cell size (Gao and Pan, 2001; 
Potter et al., 2001). The TSC1-TSC2 complex inhibits the activity of the GTPase protein 
Rheb (Ras homolog enriched in brain) by driving the hydrolysis of bound GTP in the 
Rheb protein through its GAP activity and converting Rheb to its GDP bound state which 
is inactive (Hay and Sonenberg, 2004; Jewell et al., 2013). Further studies then firmly 
established Akt as the upstream kinase that directly phosphorylates and inhibits TSC2’s 
GAP activity (Inoki et al., 2002; Manning et al., 2002). Rheb is a direct upstream 
activator of MTOR and activates MTOR’s kinase activity via a still unknown mechanism 
and thus inhibition of TSC1-TSC2 complex by Akt will ultimately lead to the activation 
of MTORC1 activity in the presence of growth factors (Inoki et al., 2003; Yuan et al., 
2013). Therefore, cells with a defective TSC1-TSC2 complex have highly elevated levels 
of GTP-bound RHEB and thus a constitutively activated MTORC1 signaling pathway 
independent of growth factors regulation (Bhaskar and Hay, 2007; Tee et al., 2002). This 
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phenomenon is particularly manifested in diseases like TSC. TSC is an autosomal 
dominant genetic disorder that is characterized by the growth of benign tumors in 
multiple organs due to loss-of-function mutations in either TSC1 or TSC2  gene, resulting 
in the loss of functional TSC1-TSC2 protein complex (Kwiatkowski and Manning, 2005).   
On the other hand, MTORC1 activity is known to be tightly regulated by its ability to 
sense the presence of amino acids as MTORC1 activity cannot be fully activated in the 
absence of amino acids despite the presence of growth factors and other nutrients (Sancak 
et al., 2008). The exact mechanisms through which intracellular amino acids are sensed 
by MTORC1 have being gradually elucidated by a series of studies. The Rag GTPases 
family in particular have been implicated as the main component of amino acid sensing 
by MTORC1 (Kim et al., 2008; Sancak et al., 2008).  Amino acids are able to activate 
heterodimers of Rag proteins by causing GTP-loaded RagA or RagB to bind to GDP-
loaded RagC or RagD. These activated heterodimers then recruit MTORC1 to the 
lysosomal surface (Sancak et al., 2010; Sancak et al., 2008). The Ragulator complex was  
identified as a guanine nucleotide exchange factor for RagA/B that activates the Rag 
GTPases (Sancak et al., 2010) and further studies have shown that this complex is 
regulated by the lysosomal vacuolar H
+
- adenosine triphosphatase (v-ATPase) that is 
sensitive to the intralysosomal amino acids levels (Zoncu et al., 2011a). Altogether, these 
studies have suggested strongly that MTORC1 is activated by signals from both the 
plasma membrane and intracellular compartments such as lysosomes.  
MTORC1 is also sensitive to the levels of glucose and ATP in the cells through AMPK, 
which is a serine/threonine kinase that acts as a sensor of the intracellular AMP:ATP ratio 
(Hardie, 2007). AMPK is activated upon metabolic stresses such as glucose starvation 
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that leads to increased levels of AMP and ADP together with decreased levels of ATP in 
cells. Activated AMPK can directly phosphorylate TSC2 and activate its GAP activity, 
leading to inhibition of MTORC1 activity (Inoki et al., 2006). Figure 4 below shows a 
detailed summary of the MTORC1 signaling pathways and the various signals that 









Figure 4: The MTORC1 signaling pathway and the various signals that converges on MTORC1 (Zoncu et 
al., 2011b).    
1.4.2 MTORC1 activates De Novo Lipogenesis               
The PI3K-Akt-MTOR signaling pathway, specifically MTORC1 has been identified as 
the upstream activator of sterol regulatory element-binding proteins (SREBPs) to 
stimulate lipogenesis in cells (Caron et al., 2010; Duvel et al., 2010; Laplante and 
Sabatini, 2009; Peterson et al., 2011; Porstmann et al., 2005; Porstmann et al., 2008). 
SREBPs are a class of basic helix-loop-helix leucine zipper (bHLH-LZ) transcription 
factors that are known to be the master regulator of almost all the genes encoding 
enzymes involved in the fatty acid and cholesterol biosynthesis (Horton et al., 2002; Shao 
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and Espenshade, 2012). There are two SREBP genes encoded in mammalian cells, 
SREBP-1 and SREBP-2 that give rise to 3 SREBP isoforms (SREBP-1a, SREBP-1c and 
SREBP-2) (Horton et al., 2002; Shao and Espenshade, 2012). SREBP-1a is known to 
activate biosynthesis of fatty acid and cholesterol, SREBP-1c activates fatty acid 
biosynthesis and lastly SREBP-2 regulates cholesterol biosynthesis and uptake. SREBP 
activity is tightly regulated through a series of complex signaling events to maintain lipid 
homeostasis in the cells. SREBPs are normally synthesized as their inactive forms on the 
surface of the ER and bound by a protein named SREBP cleavage-activating protein 
(SCAP). When the intracellular levels of lipids are depleted, SREBP will move from the 
ER to the Golgi apparatus where is it is cleaved two times in succession to produce the 
active form of the protein and finally translocates to the nucleus and turn on expression of 
its downstream target genes (Horton et al., 2002; Jeon and Osborne, 2012; Shao and 
Espenshade, 2012).  Studies using cells expressing constitutively active Akt protein or 
possessing constitutively active MTORC1 have shown that MTORC1 activity is crucial 
to activate the lipogenic phenotype in these cells via the activating the nuclear 
translocation of SREBP-1 and thus inducing its transcriptional activity (Duvel et al., 2010; 
Peterson et al., 2011; Porstmann et al., 2005; Porstmann et al., 2008). The activation of 
SREBP-1 subsequently leads to the increased expression of lipogenic enzymes like ATP 
Citrate Lyase (ACL), Acetyl-CoA Carboxylase (ACC), Fatty Acid Synthase (FASN) and 
Stearoyl-CoA desaturase 1 (SCD-1) (Duvel et al., 2010; Peterson et al., 2011; Porstmann 
et al., 2005; Porstmann et al., 2008). The exact mechanism of how MTORC1 mediates 
SREBP-1 activation is currently under intense investigation. One particular candidate that 
has been proposed to mediate SREBP-1 activation from MTORC1 signaling is Lipin-1. 
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Lipin-1 is a phosphatidic acid phosphatase that has been identified to serve as a 
transcriptional coactivator as well (Peterson et al., 2011). Under nutrient rich conditions, 
Lipin-1 is phosphorylated by MTORC1 on multiple sites and excluded from the nucleus. 
SREBP-1 is then activated and translocates to the nucleus to activate transcription of 
lipogenic genes. The authors then showed that dephosphorylation of Lipin-1 upon 
MTORC1 inhibition leads to accumulation of Lipin-1 in the nucleus. Nuclear localized 
Lipin-1 inhibits the nuclear translocation of SREBP-1 and thus blocks the expression of 
lipogenic enzymes. The exact mechanism behind how Lipin-1 is able to impair SREBP-1 
translocation is still unknown although Lamin A which is a component of the nuclear 
matrix has been proposed to play an important role. (Peterson et al., 2011; Ricoult and 
Manning, 2013). Further studies will need to be done to elucidate the mechanism through 
which phosphorylation of Lipin-1 can regulate SREBP-1 localization and activity.     
1.4.3 Altered lipid metabolism in cancer              
Actively proliferating cells usually have to satisfy the increased demand for energy and 
for the synthesis of biomolecules to ensure the doubling of protein, lipids and nucleic 
acids for each round of cell division. It is therefore understandable that cancer cells are 
often found to contain genetic mutations that lead to alterations in their cellular metabolic 
pathways to enable them to keep up with their dependence on the constant supply of 
nutrients for cell proliferation (Hanahan and Weinberg, 2011; Schulze and Harris, 2012; 
Vander Heiden et al., 2009; Ward and Thompson, 2012). Deregulated cellular 
metabolism in cancer cells has emerged as one of the important hallmarks of cancer and 
also as an effective cancer therapeutic target. Alteration of cellular metabolism in cancer 
cells was first reported by Otto Warburg in the 1920s when he showed that these cells 
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had elevated rates of glucose uptake coupled with lactate formation to produce ATP the 
presence of oxygen via a process termed ‘aerobic glycolysis’ (Warburg, 1956; Warburg 
et al., 1927). This observation is known as the Warburg effect and is one of the most 
fundamental changes attributed to cancer cells. Although the early studies on cancer cell 
metabolism focused on the reprogramming of glucose metabolism in cancer cells, it is 
now clear that cellular metabolism of amino acids and fatty acids are  altered in these 
cells and targeting these metabolic pathways represents possible therapeutic targets for 
cancer therapy (Cheong et al., 2012; Jones and Schulze, 2012).  
1.4.4 De Novo Lipogenesis in cancer              
One particular area that of cancer metabolism that has gained recognition over the last 
few years is lipid metabolism in cancer cells. One of the most commonly perturbed 
pathways in human cancers is the PI3K-Akt-MTOR signaling pathway and recent studies 
have placed it as an important upstream regulator of lipogenic phenotype in cancer cells 
via its ability to positively regulate the SREBP. (Ricoult and Manning, 2013; Santos and 
Schulze, 2012; Yecies and Manning, 2011). As summarized in Figure 5, mutations in a 
variety of oncogenes and tumour suppressors that lead to constitutive activation of 
MTORC1 will lead to elevated activity of SREBP-1 and expression of lipogenic enzymes 
that drive de novo lipogenesis (Laplante and Sabatini, 2009). One of the metabolic 
changes that is well characterized in cancer cells is the increase in de novo fatty acid 
synthesis to satisfy the increased demand for lipids that are required for membrane 
biogenesis during cell growth and proliferation (Vander Heiden et al., 2009). Although 
most cells can obtain their lipids in the form of FFAs from the bloodstream, cancer cells 




Figure 5: Constitutively activated MTORC1 leads to elevated levels of de novo lipogenesis through 
activation of SREBP-1 (Laplante and Sabatini, 2009).  
 
The increased rate of de novo fatty acid synthesis in cancer cells was first recognized 50 
years ago when elevated levels of fatty acid synthesis were observed in neoplastic tissue 
slices (Medes et al., 1953; Santos and Schulze, 2012).  It is known that most of the 
membrane phospholipids in proliferating cancer cells are obtained from esterified fatty 
acids that are synthesized de novo (Pizer et al., 1996; Swinnen et al., 2003). However, the 
importance of de novo fatty acid synthesis in cancer cells has only recently re-emerged 
when Kuhadja and Co-workers identified that the oncogenic antigen-519 (OA-519) 
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which is associated with poor prognosis in breast cancer patients is actually the enzyme 
FASN (Kuhajda et al., 1994). Majority of the subsequent studies on the lipogenic 
phenotype in cancer cells has been focused on elucidating the mechanisms controlling the 
increased rate of fatty acid synthesis in cancer cells, as well as on targeting FASN for 
cancer therapy (Mashima et al., 2009; Menendez and Lupu, 2007). It is now known that 
apart from increased expression of FASN, other enzymes such as ACL, ACC and long 
chain elongase ELOVL7 which are involved in de novo fatty acid synthesis are  up-
regulated as well (Chajes et al., 2006; Deberardinis et al., 2008; Hatzivassiliou et al., 
2005; Tamura et al., 2009). In cancer cells, excess pyruvate which is the end product of 
glycolytic cycle can be directed to de novo fatty acid synthesis. Pyruvate is converted to 
citrate in the mitochondria via the tricarboxylic acid (TCA) cycle and the citrate is then 
transported out to the cytosol and converted to acetyl-CoA by ACL. The rate limiting step 
of fatty acid synthesis requires conversion of acetyl-CoA to malonyl-CoA via ACC, a 
process that requires the consumption of an ATP molecule. FASN then performs the 
successive condensation reactions of acetyl-CoA and malonyl-CoA to produce the final 
product, the 16 carbon saturated PA. Elongation of PA can then take place through the 
elongases to form longer chain FAs and desaturation of the FAs can also take place that 
involves desaturases to produce unsaturated FAs (Deberardinis et al., 2008; Menendez 
and Lupu, 2007; Santos and Schulze, 2012).        
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1.5 Role of SCD-1 in cancer metabolism  
1.5.1 Introduction to SCD-1              
While FASN has been the main lipogenic enzyme being studied primarily as a potential 
therapeutic target in cancer (Mashima et al., 2009; Menendez and Lupu, 2007), the 
potential of targeting SCD-1 in cancer therapy has recently gained substantial attention. 
SCD-1 is an ER bound enzyme that catalyzes the formation of the first double bond at the 
cis-Δ9 position of SFAs to form MUFAs, the essential building blocks for a whole range 
of lipids, including neutral lipids and glycerolphospholipids (Hodson and Fielding, 2012; 
Ntambi and Miyazaki, 2003). SCD-1 converts palmitoyl-CoA (16C:0) and stearoyl-CoA 
(18C:0) to palmitoleoyl-CoA (16C:1) and oleoyl-CoA (18C:1), respectively. Therefore, 
the primary role of SCD-1 is to regulate the ratio of the saturated and unsaturated fatty 
acyl species of phospholipids that make up the cellular membrane to ensure the optimal 
membrane fluidity in the cells (Hodson and Fielding, 2013; Ntambi and Miyazaki, 2003). 
In mouse, there are four different isoforms of SCD (1-4), of which SCD-1 is ubiquitously 
expressed in most tissues and has been the best studied isoform. In humans, two SCD (1 
and 5) isoforms have been found with 85% homology to the mouse SCD-1 (Sampath and 
Ntambi, 2006). Expression of SCD-1 is highly regulated in cells and sensitive to a wide 
range of nutrients, including carbohydrates (Miyazaki et al., 2004), fatty acids and 
cholesterol (Ntambi, 1999). Apart from nutrient regulation, SCD-1 expression in the cells 
can  be positively regulated by numerous hormones and growth factors such as insulin 
(Waters and Ntambi, 1994), transforming growth factor-β (Samuel et al., 2002), 
fibroblast growth factor receptor 3 (Du et al., 2012) and retinoic acid (Samuel et al., 2001) 
as well. The role of SCD-1 in the development of metabolic diseases such as obesity and 
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diabetes has been well documented. It was observed that there was no accumulation of 
TAG and cholesterol esters in the livers of SCD-1 knock-out mice and TAG levels could 
not be restored despite supplementation with a lipogenic diet (Miyazaki et al., 2001). 
These findings thus suggest that de novo synthesized MUFAs by SCD-1 are the main 
substrates for production of TAG and cholesterol esters in the liver (Man et al., 2006). 
Furthermore, other studies have reported that SCD-1 played a role in energy homeostasis 
in the body as SCD-1 knock-out mice or mice injected with SCD1-specific antisense 
oligonucleotide inhibitors displayed reduced amount of adipose tissues, increased insulin 
sensitivity and were resistant to obesity (Hodson and Fielding, 2012; Jiang et al., 2005; 
Ntambi et al., 2002; Sampath and Ntambi, 2006).  
1.5.2 SCD-1 as therapeutic target in cancer               
Recent studies into malignant cell transformation and subsequent proliferation have 
suggested a critical role for SCD-1 in the development of cancer. As discussed above 
cancer cells have increased rate of glycolysis and de novo fatty acid synthesis. Apart from 
increased expression of SCD-1 due to increased SREBP-1 activity in cells with 
hyperactivated MTORC1 (Duvel et al., 2010; Peterson et al., 2011; Porstmann et al., 
2005; Porstmann et al., 2008), there is increased levels of MUFAs in cancer cells, 
implicating MUFAs as an important end product of altered glucose metabolism (Igal, 
2010; Scaglia et al., 2005).  Initial studies found elevated levels of SCD-1 expression in 
the livers of mice that are susceptible to hepatocarcinogenesis, indicating an important 
role of SCD-1 in tumor formation (Falvella et al., 2002).  It was then proposed that the 
SCD-1 activity was required for the anchorage-independent cell growth and survival, a 
major characteristic of cancer cell (Scaglia et al., 2005; Scaglia and Igal, 2005, 2008). 
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Furthermore, SCD-1 was identified through a siRNA screen to be a potential target for 
inducing cytotoxicity in cancer cells (Morgan-Lappe et al., 2007). Indeed, SCD-1 was 
found to be over expressed in many types of cancer cells and suppression of SCD-1 using 
either chemical inhibitors or genetic knockdown of SCD-1 was able to inhibit cell 
proliferation and ultimately induce cell death both in vitro and in mice xenograft models 
(Fritz et al., 2010; Hess et al., 2010; Mason et al., 2012; Minville-Walz et al., 2010; 
Scaglia et al., 2009). Interestingly, in comparison to inhibition of other lipogenic enzymes 
such as FASN and ACC, inhibition of SCD-1 was found to be most potent in killing of 
colon cancer cells in vitro and in vivo with the xenograft model (Mason et al., 2012). 
These results not only imply that SCD-1 is essential for cancer cell proliferation and 
survival, but also suggest that SCD-1 is important for lipogenesis in cancer cells and 
production of SFAs by FASN alone is not sufficient to sustain cancer cell growth. More 
importantly, inhibition of SCD-1 activity only affects the proliferation and survival of 
cancer cells but not normal, non-transformed cells indicate that specificity of this 
potential cancer therapeutic strategy (Hess et al., 2010; Minville-Walz et al., 2010; 
Scaglia et al., 2009).  
The exact mechanisms through which SCD-1 regulates cancer cell proliferation and how 
SCD-1 inhibition can lead to cell death are not well known. As discussed earlier, SFAs 
like PA which are the end products of de novo fatty acid synthesis by FASN are known to 
cause lipotoxicity in cells. Since cancer cells have elevated rates of fatty acid synthesis, it 
is imperative for them to convert excess SFAs to the non-lipotoxic MUFAs via SCD-1. 
The fact that overexpression of SCD-1 in cells treated with supra-physiological amounts 
of PA can rescue the cells from lipotoxicity is proof of the cytoprotective effect of SCD-1 
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in response to excess SFAs (Listenberger et al., 2003; Matsui et al., 2012). Inhibition of 
SCD-1 activity has also been suggested to lead to inhibition of signaling pathways 
required for cell growth and proliferation. For example, loss of SCD-1 activity was 
shown to directly lead to inhibition of PI3K-Akt-MTOR signaling pathway in both lung 
and prostate cancer models (Fritz et al., 2010; Scaglia and Igal, 2008). Akt is important 
for the activation of MTORC1 that regulates major cellular processes such as protein and 
lipid synthesis, mitochondrial biogenesis and energy homeostasis (Jewell and Guan, 2013; 
Laplante and Sabatini, 2012; Yuan et al., 2013). Furthermore, Akt inactivation will lead 
to dephosphorylation and activation of proteins including the FoxO family and glycogen 
synthase-3β (GSK-3β), all of which have been implicated in promoting cell cycle 
inhibition and induction of cell death (Burgering and Kops, 2002; Jope and Johnson, 
2004). The mechanism through which SCD-1 can activate PI3K-Akt-MTOR signaling 
pathway remains unknown. A very recent study has suggested that SCD-1 activity is 
required to maintain the MUFA/SFA ratio of the fatty acyl chains on the phospholipids of 
the plasma membrane in human lung cancer cells (Nashed et al., 2012). The authors 
showed that inhibition of SCD-1 activity will lead to alterations in the membrane fluidity 
and thus affect the lateral mobility of the lipid microdomain or lipid rafts, ultimately 
leading to defective EGFR signaling and inhibition of downstream Akt/Erk signaling 
(Nashed et al., 2012). These observations thus suggest that inactivation of Akt signaling 
caused by SCD-1 inhibition could be due to disruption of signaling cascade at the 
tyrosine kinase receptors at the plasma membrane. Proper functioning of tyrosine kinase 
receptors is known to be dependent on lipid rafts on the plasma membrane (Pike, 2009; 
Simons and Toomre, 2000). Therefore, the increased activity of SCD-1 in cancer cells 
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might be essential to maintain functional lipid raft structures on the plasma membrane via 
the production of MUFAs. More studies will need to be conducted to investigate whether 
lipid rafts are indeed affected by SCD-1 inhibition in cancer cells and whether this 
inactivation of growth signaling pathways is the main cause of cell death in cancer cells 
when SCD-1 is inhibited.         
1.6 Aims of the Study 
Thus far the role of autophagy in regulating lipid metabolism has been reported 
(Settembre et al., 2013; Singh et al., 2009a), while the regulatory functions of specific 
lipid species on the autophagic process remain largely controversial. On the other hand, 
the role of FFAs in lipotoxicity has been well studied (Schaffer, 2003; Unger, 2002), 
while the involvement of autophagy in such lipotoxicity has not been fully elucidated. 
Therefore, in the first part of this study our main objectives are to focus specifically on 
different types of FFAs in regulation of autophagic activity, with the following specific 
aims:  
1. To investigate whether different types of FFAs, namely SFA and MUFA can 
regulate autophagy during lipotoxic stresses. 
2. To determine the secondary lipid metabolites and the relevant molecular 
mechanisms directly involved in the regulation of autophagy upon FFAs-induced 
lipotoxicity.  
3. To examine the physiological roles of autophagy during FFAs induced 
lipotoxicity. 
On the other hand, cells deficient in the functional TSC1-TSC2 complex possess a 
constitutively activated MTORC1 signaling pathway that is independent of growth 
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factors regulation (Li et al., 2004; Tee et al., 2002). The activation of MTORC1 signaling 
pathway results in increased de novo lipogenesis in the cells via increased expression of 
lipogenic enzymes like FASN and SCD-1 (Duvel et al., 2010; Peterson et al., 2011; 
Porstmann et al., 2005; Porstmann et al., 2008). However, it is not known whether 
alteration of intracellular fatty acid levels in cells can affect the autophagic process. 
Therefore, in the second part of this study, we decided to investigate how alterations of 
intracellular SFAs and MUFAs will impact on the autophagic activity in the cells, with 
the following specific aims: 
1. To investigate whether alterations of intracellular SFA and MUFA levels via the 
inhibition of SCD-1 can regulate autophagy levels. 
2. To elucidate the signalling mechanisms involved in autophagy regulation upon 
inhibition of SCD-1 activity. 
3. To determine the physiological roles of autophagy during SCD-1 inhibition in 











2. Material and Methods 
2.1 Antibodies and Reagents 
BAPTA-AM, chloroquine diphosphate (CQ), crystal violet, Doxycycline, Earles’ 
balanced salt solution (EBSS), methyl-β-cyclodextrin (MBCD), propidium iodide, 12-O-
tetradecanoylphorbol-13-acetate (TPA), water-soluble cholesterol, rapamycin, myriocin, 
fumonisin B1, anti-HA, anti-LC3 and anti-tubulin antibodies were purchased from 
Sigma-Aldrich. Palmitic acid (PA), Oleic acid (OA) and essentially fatty acid free bovine 
serum albumin (BSA) were  purchased from Sigma-Aldrich and both fatty acids were 
conjugated to the fatty acid free albumin as described previously (Listenberger and 
Brown, 2007). Anti-Atg5-Atg12 antibodies were purchased from Nanotools. Anti-PKC-α 
and anti-caveolin-1 antibody was purchased from BD Transduction Laboratory. Anti-
Atg7 antibody was obtained from ProSci while anti-phospho tyrosine antibody Clone 
4G10 and anti-phospho-PKC-α antibodies were obtained from Millipore. The PKC 
chemical inhibitors GF109203X, Gö6976 and Rottlerin were purchased from Calbiochem. 
Anti-Sin 1 antibody was purchased from Bethyl Laboratories. The SCD-1 chemical 
inhibitor CAY-10566 (CAY) was purchased from Cayman Chemicals. DQ
TM
 Red BSA 
and Cholera Toxin Subunit B (CTxB) was purchased from Invitrogen. Anti-SCD-1 
antibody was purchased from Santa Cruz. The FoxO1 chemical inhibitor AS1842856 (AS) 
was purchased from Merk. All other antibodies were obtained from Cell Signaling.  
2.2 Cells and Cell Culture 
Mouse embryonic fibroblasts (MEFs) and HepG2 cells were maintained in Dulbecco’s 
modified Eagle’s medium (DMEM, from Sigma) containing 10% fetal bovine serum 
(HyClone) and 1% penicillin/streptomycin (Invitrogen) (defined as full medium in this 
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study) in a 5% CO2 atmosphere at 37 °C. The Wild-type (WT) and Atg5 knock-out (KO) 
mouse embryonic fibroblasts (MEFs ) and the Tet-off Atg5 MEFs were provided by Dr. 
N. Mizushima (Tokyo Medical and Dental University) (Hosokawa et al., 2007). In most 
of the experiments, cells were treated with 0.25mM of PA or OA in high glucose, serum 













MEFs hereafter) and maintained in Dulbecco’s modified Eagle’s medium (DMEM, from 
Sigma) containing 10% fetal bovine serum (HyClone) and 1% penicillin/streptomycin 
(Invitrogen) in a 5% CO2 atmosphere at 37°C as well. The Tsc2
-/- 
MEFs reconstituted 
with either empty vector (+EV) or TSC2 protein (+TSC2) were a generous gift from Dr. 
BD Manning (Huang et al., 2008) and maintained in the same conditions as above.     
2.3 Immunoblotting and Immunoprecipitation 
Immunoblotting analysis was performed following the established procedures. The cells 
were lysed in Laemmli SDS buffer containing: 62.5 mM Tris at pH 6.8, 25% glycerol, 2% 
SDS, phosphatase inhibitor mixture (Pierce), and the protease inhibitor mixture (Roche 
Applied Science). Equal amount of protein for each sample was resolved on SDS-PAGE 
gel and transferred onto polyvinylidene difluoride (PVDF) membrane (Bio-Rad). After it 
was blocked with 5% non-fat milk, the membrane was then probed with the designated 
primary and secondary antibodies and subsequently developed with the enhanced 
chemiluminescence method (Pierce) and visualized by a Kodak Image Station 4000R 
(Kodak). The immunoprecipitation (IP) assay was performed as described previously 
with slight modifications (Ikenoue et al., 2009). Briefly the cells were lysed for 30 
minutes in the IP buffer (40 mM HEPES, pH 7.4, 120 mM NaCl, 2 mM EDTA, 0.3% 
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CHAPS, 10 mM pyrophosphate, 10 mM glycerophosphate, 50 mM NaF, phosphatase and 
protease inhibitor mixture). Cell lysates containing the same amount of protein were 
incubated with 1 µg of antibody and mixed overnight at 4°C with gentle rocking. After 
incubation overnight, 30 µl of Sepharose protein A/G-agarose beads were added to the 
cell lysates and mixed for 1 hour at 4°C with gentle rocking. After incubation, the beads 
were washed extensively with the IP buffer for five times, and the immunoprecipitated 
proteins were eluted by boiling for 5 minutes in sample buffer (Bio-Rad) before being 
resolved on SDS-PAGE gel and transferred onto PVDF membrane (Bio-Rad) for 
immunoblotting. All densitometry and quantification for the LC3-II western blots were 
calculated using the Kodak 1D 4.5.1 software by normalizing to the levels of LC3-II in 
the control treatments.   
2.4 Sample Processing and Imaging for Transmission Electron 
Microscopy 
MEFs were seeded on 4-chambered coverglass (NUNC Lab-tek Chambered Coverglass 
System) at a density of 2 X 10
4
 cells/ml. After the respective treatments for 4 hours, cells 
were fixed with 2.5% glutaraldehyde and washed 3 times with 1 x phosphate buffer saline 
(PBS). Subsequently, post-fixation with 1% osmium tetroxide was performed followed 
by dehydration with ascending series of alcohol before being embedded in araldite for 24 
hours. Ultrathin sections of 99 nm thickness were cut with a glass knife on the Reichert 
Ultracut E ultramicrotome, mounted onto copper grids and doubly stained with uranyl 
acetate and lead citrate. Images were acquired using the JEOL JEM1010 transmission 




2.5 Confocal Microscopy 
Cells were seeded to a coverglass slide chamber (NUNC Lab-tek Chambered Coverglass 
System) and after the designated treatments, the cells were examined under a confocal 
microscope (Olympus Fluoview 1000). GFP-LC3 puncta in the cells were quantified by 
counting the number in cells as described previously (Wu et al., 2010). Briefly, the GFP-
LC3 puncta were manually counted under the confocal microscope. 30 cells were 
randomly selected from each treatment to calculate the average number of GFP-LC3 
puncta per cell. The data shown is from one representative experiment of three 
independent repeats. For the DQ
TM
 Red BSA assay, DQ
TM
 Red BSA (10 µg/ml) was 
added for the last hour of treatment and cells were then observed under the confocal 
microscope. For staining of lipid rafts, the cells were incubated with Cholera Toxin 
Subunit B (CTxB, 10 µg/ml) at 4°C for 15 minutes. The cells were then washed with 
PBS for 2 times and incubated for another 30 minutes at 37°C and observed immediately 
under the confocal microscope.        
2.6 Analysis of lipids using High Performance Liquid 
Chromatography/Mass Spectrometry 
An Agilent high performance liquid chromatography (HPLC) 1200 system coupled with 
an Applied Biosystem Triple Quadrupole/Ion Trap mass spectrometer (3200 Qtrap) was 
used to quantify individual phospholipids. An Agilent high performance liquid 
chromatography (HPLC) 1100 system coupled with an Applied Biosystem Triple 
Quadrupole/Ion Trap mass spectrometer (4000 Qtrap) was used for quantification of 
individual phospholipids. Samples were introduced into the mass spectrometer by loop 
injections with chloroform:methanol (1:1) as a mobile phase for both positive ESI mode 
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and negative ESI mode, respectively. Two comprehensive sets of multiple reaction 
monitoring (MRM) transitions were set up for quantitative analysis of various 
phospholipids (Shui et al., 2011b). Levels of individual lipid were quantified using spiked 
internal standards that include PC-14:0/14:0, PE-14:0/14:0, PS-14:0/14:0, PG-14:0/14:0 
(Avanti Polar Lipids, USA), and dioctanoyl PI (Echelon Biosciences, Inc., USA). Neutral 
lipids were analyzed using an Agilent 1200 HPLC system coupled with an Applied 
Biosystem Triple Quadrupole/Ion Trap (3200Qtrap) mass spectrometers.  Glycerol lipids 
were analyzed using a sensitive HPLC/ESI/SIM method modified from a previous 
method (Shui et al., 2010). HPLC conditions: Luna 3-µm silica column (i.d. 150  2.0 
mm); mobile phase A (chloroform:methanol:ammonium hydroxide, 89.5:10:0.5), B 
(chloroform:methanol:ammonium hydroxide:water, 55:39:0.5:5.5); flow rate 300 µl/min; 
5% B for 3 min, then linearly switched to 30% B in 24 min and maintained for 5 min, and 
then linearly changed to 70% B in 5 min and maintained for 7 min. Then, the 
composition of the mobile phase was returned to the original ratio over 5 min and 
maintained for 6 min before the next sample was analyzed. Multiple reaction monitoring 
(MRM) transitions for individual glycerolphospholipid species and sphingolipids were set 
up at different elution stages for LC-MS analysis (Shui et al., 2010; Shui et al., 2011b). 
Levels of individual lipid levels were quantified using spiked internal standards. Neutral 
lipids were analyzed using a sensitive HPLC/ESI/MRM method modified from a 
previous method (Shui et al., 2010). TAGs were calculated as relative contents to the 
spiked d5-TAG 48:0 internal standard (CDN isotops), while DAGs were quantified using 
4ME 16:0 Diether DG (Avanti) as an internal standard. Triacylglycerol (TAGs) were 
calculated as relative contents to the spiked d5-TAG 48:0 internal standard (CDN 
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isotops), while diacylglycerol (DAGs) were quantified using 4ME 16:0 Diether DG 
(Avanti) as an internal standard.  Cholesterol and cholesteryl esters (CE) were quantified 
using HPLC/APCI/MS/MS as previously described with corresponding d6-cholesterol 
and d6-C18 cholesterol ester (CDN isotopes) as internal standards (Shui et al., 2011a).   
2.7 Transient Small Interfering RNA (siRNA) Transfection 
The nonspecific siRNA oligonucleotides and siRNA oligonucleotides targeting mouse 
and human Atg7 and PKC-α, mouse DGAT1, SCD-1 and FoxO1 (ON-TARGETplus 
SMARTpoolTM) were obtained from Dharmacon (Layfayette, CO). The siRNAs was 
transfected into the respective cells as indicated using the DharmaFECT 4 transfection 
reagent according to the manufacturer’s protocol.  
2.8 Detection of Cell Death 
Flow cytometry was used to determine the cell viability using the live cell propidium 
iodide exclusion test, as previously described (Wu et al., 2008a). In brief, cells were 
trypsinized at the end of the experiments. Cells were washed once with PBS and 
resuspended in PBS containing 1 mg of propidium iodide/ml. The levels of propidium 
iodide incorporation were quantified by flow cytometry using a FACSCalibur flow 
cytometer. Cell size was evaluated by forward-angle light scattering. Propidium iodide-
negative cells with normal size were considered to be live cells. Morphological changes 
of treated cells under phase-contrast microscope were also observed to detect cell death 
after treatment.  
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2.9 Colony Formation Assay 
The cells were first treated as designated and then re-seeded into six-well plates at a cell 
density of 5000 cells/well. After 2 weeks, the surviving clones were stained with 0.5% 
crystal violet solution for 1 hour and photographed using a digital camera.  
2.10 Plasmids and Transfection 
The GFP-tagged LC3 plasmid was kindly provided by Dr. T. Yoshimori (Osaka 
University, Japan). The HA-Akt and Myr-HA-Akt plasmids were kindly provided by Dr. 
J. S. Gutkind (National Institutes of Health, USA). Transient transfection was performed 
using the Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer’s 
protocol. Briefly, the cells were transfected with the plasmids for 24 hours and re-seeded 
overnight before being subjected to the designated treatments. 
2.11 Separation of Detergent-Soluble and Detergent-Resistant Fraction 
Separation was conducted as described previously with modifications (Wu et al., 2008b). 
Cells were collected after their designated treatments and lysed in TNE buffer containing 
150 mM NaCl, 0.5% Triton X-100, 3mM EDTA, 20 mM Tris HCl (pH 7.5) with 
phosphatase and protease inhibitor mixture. The cells were then homogenized by passage 
through a 23-gauge needle for 10 times and incubated for 1 hour on ice. The lysates were 
then centrifuged at 14,000 g for 30 minutes at 4°C and the supernatants were collected as 
the detergent-soluble fraction. The remaining pellets were resuspended and briefly 
sonicated in the same lysis buffer supplemented with 0.5% SDS and 2 mmol/L DTT and 
the supernatant were collected as the detergent-resistant fractions. 
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2.12 Preparation of Nuclear and Cytosolic Extracts  
After designated treatments, the nuclear and cytosolic extracts were prepared using the 
NE-PER
®
 nuclear and cytoplasmic extraction reagents (Pierce), according to the 
manufacturer’s protocol. 
2.13 Dual-Luciferase Reporter Assay 
The WT FoxO1-Luc and mutant FoxO1 (mut 1 +2)-luc vectors were described in a 
previous study (Al-Mubarak et al., 2009). Transient transfection of FoxO1-Luc and the 




 MEFs using Lipofectamine 
2000 reagent (Invitrogen) according to the manufacturer’s protocols. The Renilla 
luciferase vector was cotransfected together as a transfection control. The cells were then 
treated with CAY for the time indicated 24 hours after transfection. The luciferase 
activity was then measured using a Dual-Luciferase Reporter Assay System (Promega, 
E1960) based on the protocol provided by the manufacturer. Briefly, the treated cells 
were lysed with the addition of cell lysis reagent and the individual cell lysates were 
collected. The firefly luciferase activity was determined using the luminometer (Promega) 
after addition of the luciferase assay substrate to a fixed amount of cell lysate. The 
Renilla luciferase activity was subsequently measured after the addition of the Stop&Glo 
substrate.  
2.14 Reverse Transcription and Quantitative Real-Time PCR 
The total RNA was extracted with the RNeasy kit (Qiagen). A reverse transcription 
reaction was then performed using 1 µg of total RNA with High Capacity cDNA Reverse 
Transcription kit (Applied Biosystems). The mRNA expression levels of target genes 
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were then determined by real-time PCR using SsoFast™ EvaGreen® Supermix (Bio-Rad) 
and CFX96 Touch™ Real-Time PCR Detection System (Bio-Rad). Glyceraldehyde-3- 
phosphate dehydrogenase (GAPDH) was used as an internal control. The primers used in 
the study are listed as below: 
ATG4: Forward primer: ATT GCT GTG GGG TTT TTC TG  
Reverse primer: AAC CCC AGG ATT TTC AGA GG 
 
ATG12: Forward primer: GGC CTC GGA ACA GTT GTT TA  
Reverse primer: CAG CAC CGA AAT GTC TCT GA  
 
BNIP3: Forward primer: TTC CAC TAG CAC CTT CTG ATG A  
Reverse primer: GAA CAC CGC ATT TAC CAG AAC AA 
 
BNIP3L: Forward primer: TTG GGG CAT TTT ACT AAC CCT G  
Reverse primer: TGC AGG TGA CTG GTG GTA CTA A 
 
BECLIN1: Forward primer: GGC CAA TAA GAT GGG TCT GA  
Reverse primer: CAC TGC CTC CAG TGT CTT CA  
 
LC3B: Forward primer: CGT CCT GGA CAA GAC CAA GT  
Reverse primer: ATT GCT GTC CCG AAT GTC TC 
 
VPS34: Forward primer: TGT CAG ATG AGG AGG CTG TG  
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Reverse primer: CCA GGC ACG ACG TAA CTT CT 
 
FASN: Forward primer: CAG CAG AGT CTA CAG CTA CCT 
Reverse primer: ACC ACC AGA GAC CGT TAT GC 
 
SCD-1: Forward primer: ACG CCG ACC CTC ACA ATT C 
Reverse primer: CAG TTT TCC GCC CTT CTC TTT 
 
GAPDH: Forward primer: TCA CCA TCT TCC AGG AGG GA 
Reverse primer: GCA TTG CTG ACA ATC TTG AGT GAG 
2.15 Statistics  
The numerical results are all expressed as mean ± standard deviation (S.D.) from at least 












3.1 Induction of autophagy by palmitic acid via protein kinase C-
mediated signaling pathway independent of MTOR 
3.1.1 PA, but not OA, induces autophagy 
As mentioned above many studies have concluded that SFAs, such as PA are more 
cytotoxic compared to unsaturated fatty acids, such as OA (Cunha et al., 2008; 
Listenberger et al., 2003; Listenberger et al., 2001; Maedler et al., 2001; Malhi et al., 
2006; Schaffer, 2003). However, it is not known if autophagy plays a role promoting or 
preventing the cytotoxic effect of SFAs. In order to rule out the effects of FFAs that are 
commonly found in the serum that is added to culture medium, all the subsequent 
treatments with either OA or PA were conducted in serum free DMEM. Furthermore, 
cells that were cultured in DMEM without serum were also used as comparison against 
PA or OA treated cells to rule out the fact that any increase in autophagy levels could be 
due to the absence of serum. We first treated cells with PA in a time course to look at 
whether the autophagic levels could be affected in the treated cells. As shown in Figure 
6A, treatment of MEFs with PA resulted in a significant increase in the levels of LC3-II 
for up to 24 hours, in comparison to the control cells treated with BSA as control. In 
order to measure the actual changes in the autophagic flux of the PA treated cells, we 
used chloroquine (CQ) to block lysosomal function and the late degradation stage of 
autophagy (Mizushima et al., 2010). With the addition of CQ, we were able to observe a 
further increase of LC3-II level in PA-treated cells at the various time points (Fig. 6B), 
thus clearly suggesting that PA is able to induce autophagy flux in MEFs. To further 
confirm the observation that PA treatment does indeed induce autophagy in the MEFs,  
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Figure 6. PA treatment induces autophagy. (A) MEFs were treated with PA (0.25 mM) conjugated to 
fatty acid free BSA for the different time points as indicated. Cells treated with BSA acted as control. FM: 
full medium (DMEM) with 10 % FBS. After treatments, cell lysates were collected and subject to western 
blot. (B) MEFs were treated with PA (0.25mM) for the indicated time points, with or without the addition 
of CQ (10 µM). C. MEFs were treated with BSA (panel a), PA (0.25 mM, panel b), OA (0.25 mM, panel c) 
or EBSS (panel d) for 4 hours before being processed and cellular images were then taken using an electron 
microscope at 2500X and 40000X magnification.   
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transmission electron microscopy studies were performed on MEFs under various 
treatments. As shown in Figure 6C, autophagosome like vacuoles were hardly seen in 
BSA-treated control cells (panel a). In contrast, we observed an increase in the formation 
of autophagosome like structures containing cytosolic contents in the PA-treated MEFs 
after 4 hours (panel b, white arrows). Similar autophagosome like vacuoles containing 
cytosolic contents were observed as well in MEFs treated with EBSS as a positive control 
(Fig. 6C, panel d, white arrows). However, no autophagosome like vacuoles containing 
cytosolic contents were observed in MEFs treated with OA for 4 hours (Fig. 6C, panel d), 
suggesting that OA treatment was not able to induce autophagy.      
ATG5 protein is essential for the completion of the autophagosome and loss of ATG5 
leads to disruption of autophagosome formation and inhibits the autophagic process 
(Nakatogawa et al., 2009; Yang and Klionsky, 2010b). However, a recent study has 
shown that autophagy can be induced despite the loss of ATG5 protein in cells (Nishida 
et al., 2009). Therefore we next examined whether PA-induced autophagy is dependent 
on the presence of ATG5 and the canonical autophagy machinery. As shown in Figure 
7A, no LC3-I to LC3-II conversion was observed in the Atg5 knock-out (KO) MEFs we 
used compared to the WT cells and we observed a dose dependent increase in the LC3-II 
levels upon treatment with increasing doses of PA in the WT MEFs. Similar observation 
was seen using the WT and Atg5 KO MEFs when they were starved in the EBSS medium 
as well. These results suggest that PA-induced autophagy is dependent on the canonical 
autophagy induction machinery. To further validate the results, we utilized the MEFs 
with the inducible Atg5 deletion system that stably express GFP-LC3 (Hosokawa et al., 
2007) to further evaluate PA-induced autophagy. There was a significant increase in 
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GFP-LC3 puncta in PA-treated cells expressing the ATG5 protein where no doxycycline 
(DOX) was added (Fig. 7B). Consistently, we observed that addition of CQ together with 
PA treatment further enhanced both the size and the number of such GFP-LC3 puncta in 
the cells, suggesting an increase in autophagic flux. Similar to the results in Figure 6A, 
deletion of Atg5 by addition of DOX abolished the effect of PA on GFP-LC3 puncta 
formation further confirming that autophagy induction by PA treatment is dependent on 
the canonical autophagy machinery. Finally, we compared the effects of PA treatment 
with that of the MUFA, OA on autophagic activity in the treated MEFs. Treatment of the 
MEFs with OA at similar concentration to that of PA (0.25 mM) for 4 hours did not cause 
any significant increase in the levels of LC3-II conversion, even with the presence of CQ 
(Fig. 7C). On the other hand, treatment of the cells with PA and other known autophagy 
inducers (EBSS and rapamycin) were able to cause an evident increase in the autophagic 





Figure 7. PA induced autophagy is dependent on the canonical autophagy machinery. (A) WT and 
Atg5 KO MEFs were treated various concentrations of PA for 4 hours. (B) Atg5 Tet-off MEFs stably 
expressing GFP-LC3 were treated with PA (0.25 mM) for 4 hours and GFP-LC3 puncta formation was 
observed using confocal microscopy. Atg5 protein expression was inhibited in the cells cultured with DOX 
for 4 days. The number of GFP-LC3 puncta/cell were then counted (**p<0.01, student’s t-test).  (C) MEFs 
were treated with either BSA, PA (0.25 mM) or OA (0.25 mM) for 4 hours with or without the addition of 
CQ.   
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3.1.2 PA-induced autophagy is independent of the MTORC1 signaling pathway 
Since the MTORC1 signaling pathway is well established as the key negative regulator of 
the autophagic process (Jung et al., 2009; Mizushima, 2010), we next investigated the 
role of the MTORC1 signaling pathway in PA-induced autophagy. The p70 S6 kinase 
(p70S6K) protein is a direct substrate of MTORC1 and its phosphorylation status can be 
used as an indicator of the activity of the MTORC1 pathway (Laplante and Sabatini, 2012; 
Zoncu et al., 2011b). When MEFs were treated with either BSA or PA in FBS-free 
medium, there was a marked reduction of the p-p70S6K level compared to the cells in 
normal full medium (FM) conditions (Fig. 8A). However, we observed no further 
decrease in the levels of p-p70S6K levels in the PA treated cells compared to the BSA 
treated cells, especially at the earlier time points (Fig. 8A). Interestingly, PA increased 
the p-p70S6K level at later time points (12 and 24 hours). The same trends were also 
observed for the direct substrate of p70S6K, the S6 ribosomal protein (Fig. 8A), 
indicating the possibility that PA may activate MTORC1 with prolonged treatment. 
To further confirm the above observations, the MEFs were then treated with PA in FM 
which contains 10% fetal bovine serum (FBS). Other known inducers of autophagy like 
EBSS treatment and rapamycin are known to induce autophagy via inhibition of the 
MTORC1 signaling pathway.  As shown in Figure 8B, treatment of MEFs with EBSS or 
rapamycin resulted in complete loss of phosphorylation on the p70S6K and S6 ribosomal 
proteins implying inhibition of MTORC1 concurrently with an increase in autophagic 
activity (Fig. 8B). Furthermore, treatment with PA for 4 hours led to an increased 
conversion of LC3-I to LC3-II levels and addition of the lysosomal inhibitor CQ further 
enhanced the increase of LC3-II levels, indicating an increase in autophagic flux in the 
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PA-treated cells. On the other hand, there was no further increase in autophagic flux 
observed in the cells treated with BSA. Consistently, we observed that PA treatment 
failed to reduce the phosphorylation levels of p70S6K and S6 ribosomal protein despite 
the induction of autophagy observed in the MEFs (Fig. 8B), suggesting that MTORC1 
activity was not inhibited upon PA treatment. Thus the results here suggest that PA-
induced autophagy is independent of the canonical MTORC1 signaling pathway 
regulation.  
In order to investigate whether PA-induced autophagy can be observed in other cell types, 
we then treated the liver cell line HepG2 with various autophagy inducers. Indeed, 
treatment of HepG2 cell with PA significantly enhanced the levels of autophagic flux 
observed compared to the BSA treated cells (Fig. 9A). Furthermore, OA treatment did 
not did not result in any further increase in the autophagic flux when compared to the 
BSA-treated control cells (Fig. 9A), confirming the earlier observations that only PA 
treatment resulted in autophagy induction.  Consistently, when the HepG2 cells were 
treated with PA in FM containing 10% FBS for 4 hours, an increase in autophagic flux 
was observed with no inhibition of the MTORC1 signaling pathway (Fig. 9B). Such 
results enforced the observation that induction of autophagy by PA is independent of the 





Figure 8. PA-induced autophagy is independent of the MTORC1 regulation. (A) MEFs were treated 
with BSA or PA (0.25 mM) for various time points as indicated. Cell lysates were collected and subject to 
western blot. (B) MEFs were treated with BSA control or PA (0.25 mM) for 4 hours in FM. Cells were 
treated with EBSS and the MTOR inhibitor, rapamycin (20 nM) for 4 hours as positive controls. CQ (10 





Figure 9. PA also induces autophagy in HepG2 cells which is independent of MTORC1 regulation. (A) 
HepG2 cells were treated with BSA, PA (0.25 mM) or OA (0.25 mM) for 4 hours with or without the 
addition of CQ (10 μM). Treatment with EBSS was used as a positive control for autophagy induction in 
the HepG2 cells. (B) HepG2 cells were treated with BSA control or PA (0.25 mM) for 4 hours in FM. CQ 
(10 μM) was added to the treated cells to determine the level of autophagic flux in the cells.   
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3.1.3 Accumulation of intracellular ceramide is not related to PA-induced 
autophagy  
The accumulation of intracellular ceramides have been linked to the progression of 
diseases like obesity and other metabolic diseases as described earlier (Holland and 
Summers, 2008; Kihara et al., 2007; Zheng et al., 2006). The first and rate-limiting step 
of de novo ceramide synthesis involves the condensation of serine with palmitoyl-CoA to 
form 3-ketodihydrosphingosine which is then converted via subsequent reactions into 
ceramides (Kihara et al., 2007). The treatment of the cells with exogenous PA could 
possibly cause an increase in ceramide production in the cells since PA can act as a 
source of palmitoyl-CoA. More importantly, a few studies have reported that treatment 
with short chain ceramides can induce autophagy in a variety of cancer cell lines due to 
promotion of long chain ceramide synthesis (Guenther et al., 2008; Pattingre et al., 2009; 
Scarlatti et al., 2004). Therefore we next investigated whether ceramides played any role 
in the induction of autophagy caused by PA treatment. Here we first measured the levels 
of intracellular ceramides in cells treated with either PA or OA. Treatment with PA for 4 
hours resulted in an increase of ceramides by about 1.4 fold compared to the cells treated 
with BSA control although it was not statistically significant; while very marginal 
increase was found in the OA-treated cells (Fig. 10A). To further test the effects of 
intracellular ceramides on PA-induced autophagy, cells were treated with the chemical 
inhibitor of serine palmitoyltransferase, myriocin or the inhibitor of sphingosine N-
acyltransferase fumonisin B1 (FB1), as both of these enzymes are essential for the de 
novo synthesis of ceramide in cells
 
(Pattingre et al., 2009; Scarlatti et al., 2004). Addition 
of myriocin or FB1 to PA-treated cells did not inhibit the increase in LC3-II conversion 
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observed when compared to the cells treated with PA only (Fig. 10B). Furthermore, the 
increase in overall autophagic flux was not affected by the inhibition of ceramide 
synthesis as observed by the cells treated together with CQ (Fig. 10B). To further validate 
these results, we then inhibited ceramide synthesis using FB1 in the MEFs stably 
expressing GFP-LC3. Consistently, inhibition of de novo ceramide synthesis with FB1 
failed to reduce the formation of GFP-LC3 puncta formed in the PA-treated cells, with or 
without the presence of CQ (Fig. 10C). Altogether, results from this part of the study 
strongly suggest that endogenous ceramide levels are not related to PA-induced 
autophagy.  
3.1.4  PA, but not OA, induces accumulation of intracellular diacylglycerol 
FFAs are the immediate precursors that can be used for de novo synthesis of neutral lipids 
like TAG and DAG (Coleman and Mashek, 2011). Both DAG and TAG are glycerolipids, 
with either 2 or 3 fatty acid chains linked to the glycerol molecule respectively. When 
taken up by cells, excess FFAs can be converted into their respective acyl-CoA 
derivatives (Coleman and Mashek, 2011). These acyl-CoA derivatives can then be 
incorporated and stored in the cells in the form of neutral lipids like DAG and TAG (Li et 
al., 2010; Listenberger et al., 2003). Thus we hypothesized that the intracellular levels of 
DAG and TAG will increase substantially during PA or OA treatment. Therefore we 
proceeded to measure the levels of intracellular DAG and TAG after treatment with 
various concentrations of PA or OA. MEFs were treated with either BSA as control or 
0.125 mM and 0.25 mM of either PA (Fig. 11A) or OA (Fig. 11B) for 1, 2 and 4 hours. 




Figure 10. Autophagy induction by PA is not caused by intracellular accumulation of ceramide. (A) 
MEFs were treated with BSA, PA (0.25 mM) or OA (0.25 mM) for 4 hours and the total ceramide levels 
were then quantified. The relative ceramide levels of cells from the various treatments were calculated by 
normalizing to the ceramide levels of the cells treated with BSA. Data were presented as means ± S.D. of 
three independent experiments. (B) MEFs were treated with BSA or PA (0.25 mM) for 4 hours with or 
without the presence of either myriocin (1 µM) or FB1 (10 µM). CQ (10 µM) was added to the treated cells 
to observe the changes in the autophagic flux. (C) Atg5 Tet-off MEFs stably expressing GFP-LC3 were 
treated with either BSA or PA (0.25 mM) for 4 hours with or without the presence of FB1 (10 µM) and the 
number of GFP-LC3 puncta/cell were quantified (**p<0.01, student’s t-test).    
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As expected, we observed that treatment with either PA or OA resulted in a dose and time 
dependent increase in the relative levels of DAG and TAG compared to the BSA-treated 
control cells (Fig. 11A, left panel). Furthermore, although TAG levels in the PA-treated 
cells also increased significantly at treatment times up to 4 hours, we observed that the 
rate of increase in TAG level was not proportional to that of DAG with 0.25 mM of PA 
treatment (Fig. 11A, right panel).  
On the other hand, the accumulation of DAG in the MEFs that were treated with different 
concentrations of OA were not statistically significant (Fig. 11B, left panel). Instead, we 
observed a significant time and dose-dependent increase in TAG accumulation in the 
cells treated with OA (Fig. 11B, right panel).  To confirm the results from this part of the 
study, we treated the HepG2 cells with similar concentrations of PA or OA for the 
respective time points. Similar to the results observed for the MEFs, only the PA-treated 
HepG2 cells had significantly elevated levels of DAG accumulation by up to 4 hours of 
treatment but this was not seen in the OA-treated HepG2 cells (Fig. 12). Interestingly, PA 
treatment also resulted in a significant increase in the intracellular TAG levels by 4 hours 
(Fig. 12A, right panel) although the magnitude of increase was smaller when compared to 
the increase in TAG levels of the OA-treated HepG2 cells (Fig. 12B, right panel). There 
have been previous studies that have shown that the enzyme responsible for the 
conversion of DAG to TAG, diacylglycerol acyltransferase (DGAT), has a higher 
specificity for fatty acyl-CoAs that contain the 18C:1 chain derived from OA compared 
to other fatty acyl-CoAs that have the 16C:0 chain coming from PA (Coleman and Bell, 
1976; Li et al., 2010). Therefore such a substrate specificity by DGAT could well explain 
the trends observed in our data where the OA-treated MEFs and HepG2 have a much 
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more elevated levels of intracellular TAG compared to that of DAG (Fig. 11B and 12B); 
while in cells treated with PA the accumulation of intracellular DAG was more 
significant than that of the increase in TAG levels (Fig. 11A and 12A). 
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Figure 11. PA and OA treatment induce differential accumulation of intracellular DAG and TAG 
which is time and dose dependent in MEFs. (A) MEFs were treated with BSA and PA (0.125 mM and 
0.25 mM) for 1, 2 and 4 hours. The total DAG (Left panel) and TAG (Right panel) levels were then 
quantified. The relative DAG and TAG levels were calculated by normalizing their respective levels in 
each treatment at different time points to the levels present in the control cells. (B) Cells were treated with 
BSA and OA (0.125 mM and 0.25 mM) for 1, 2 and 4 hours. The total DAG (Left panel) and TAG (Right 
panel) levels were then quantified. The relative DAG and TAG levels were calculated as described in (A) 
Data were presented as means ± S.D. of three independent experiments and Student’s T-test were 
calculated between the BSA treated cells and either PA or OA treated cells at each respective time point 
(*p<0.05, **p<0.01, student’s t-test). 
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Figure 12. PA and OA treatment induce differential accumulation of intracellular DAG and TAG 
which is time and dose dependent in HepG2. (A) HepG2 cells were treated with BSA and PA (0.125 mM 
and 0.25 mM) for 1, 2 and 4 hours. The total DAG (Left panel) and TAG (Right panel) levels were then 
quantified. The relative DAG and TAG levels were calculated by normalizing their respective levels in 
each treatment at different time points to the levels present in the control cells. (B) Cells were treated with 
BSA and OA (0.125 mM and 0.25 mM) for 1, 2 and 4 hours. The total DAG (Left panel) and TAG (Right 
panel) levels were then quantified. The relative DAG and TAG levels were calculated as described in (A) 
Data were presented as means ± S.D. of three independent experiments and Student’s T-test were 
calculated between the BSA treated cells and either PA or OA treated cells at each respective time point 
(*p<0.05, **p<0.01, student’s t-test). 
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3.1.5 Inhibition of Protein Kinase C blocks autophagy induction caused by PA 
treatment  
The results from Figures 11 and 12 suggest strongly that autophagy induction caused by 
PA treatment could be due to accumulation of intracellular DAG species in the cells 
Therefore we went on to try to elucidate possible the signaling pathways that could be 
affected by elevated levels of DAG accumulation in cells. One of the well known 
signaling pathways in which DAG plays an important role during signal transduction is 
that of the DAG-PKC signaling, where DAG serves as a natural agonist to recruit PKC 
proteins to the plasma membrane for activation (Newton, 2001; Takai et al., 1979). As 
described earlier, there are essentially 3 classes of PKC family comprising a total of 10 
PKC isozymes in the mammalian system: classical, novel and atypical PKCs (Newton, 
2001; Takai et al., 1979). Amongst these PKC members, some of them have already been 
described to play a role in autophagy induction downstream of several cellular stresses 
(Chen et al., 2008; Sakaki and Kaufman, 2008; Sakaki et al., 2008). To investigate 
whether PKC was involved in PA-induced autophagy, we first made use of different 
chemical inhibitors that targeted all members of PKCs or specific classes of the PKC 
family. Firstly, GF109203X, a general PKC inhibitor, was able to markedly reduce LC3-
II levels in cells treated with PA with or without the presence of CQ (Fig. 13A). This 
observation suggested that inhibition of the PKC signaling pathway impairs PA-induced 
autophagy. Next, we tried to identify which class of PKC family was involved in PA-
induced autophagy by testing the effects of two other chemical inhibitors, Gö6976 and 
Rottlerin, which inhibit the classical and novel classes of PKC respectively. As shown in 
Figure 13B (Left panel), the classical PKC inhibitor Gö6976 was found to reduce the 
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LC3-II level in PA-treated cells, similar to the effects observed with the use of 
GF109203X. In contrast, addition of the novel PKC inhibitor Rottlerin failed to suppress 
the autophagic flux induced by PA treatment (Fig. 13B, Right panel). We further 
confirmed the effect of Gö6976 by examining GFP-LC3 puncta formation in the MEFs 
that were stably expressing GFP-LC3. Addition of Gö6976 prevented the increase in the 
formation of GFP-LC3 punctas in the PA-treated cells, again suggesting that PA-induced 
autophagy requires the presence of active classical PKC members (Fig. 13C). 
Furthermore, we were able to observe a significant decrease in LC3-II conversion and 
autophagic flux when HepG2 cells were treated with PA in the presence of Gö6976  
suggesting that the requirement of classical members of PKC for PA-induced autophagy 
is not cell type specific (Fig. 13D). All these findings indicate a possibility that members 
of the classical PKC are implicated in PA-induced autophagy. As the activation of the 
classical PKC members requires both the presence of calcium ions (Ca
2+
) and DAG 
(Newton, 2001; Takai et al., 1979), we then investigated whether PA-induced autophagy 
is sensitive to the loss of free intracellular Ca2
+
 ions in the cells. To this end, we made 
use of BAPTA-AM, an intracellular Ca
2+
 ion chelator (Sakaki et al., 2008). As expected, 
the addition of BAPTA-AM resulted in an overall decrease in autophagic flux observed 
in the PA-treated cells (Fig. 13E) suggesting that the free intracellular Ca
2+
 ions are 
involved in PA-induced autophagy.  Overall, the results from this part of our study 
support the notion that the classical group of PKC is implicated in PA-induced autophagy 










Figure 13. PA-induced autophagy requires the activation of PKC family. (A) MEFs were treated with 
BSA or PA (0.25 mM) for 4 hours with or without the presence of the general PKC inhibitor GF109203X 
(1 μM). CQ (10 μM) was added to the treated cells to determine the levels of autophagic flux. (B) MEFs 
were treated with BSA or PA (0.25 mM) for 4 hours with or without the presence of either the classical 
PKC inhibitor Gö6976 (1 μM) (Left panel) or the novel PKC inhibitor, Rottlerin (10 μM) (Right panel). CQ 
(10μM) was added to the treated cells to determine the levels of autophagic flux. (C) Atg5 Tet-off MEFs 
stably expressing GFP-LC3 were treated with either BSA or PA (0.25mM) for 4 hours with or without the 
presence of classical PKC inhibitor Gö6976 (1 μM) and the number of GFP-LC3 puncta/cell were 
quantified (**p<0.01, student’s t-test). (D) HepG2 cells were treated with BSA or PA (0.25 mM) for 4 
hours with or without the presence of the classical PKC inhibitor Gö6976 (1 μM). CQ (10 μM) was added 
to the treated cells to determine the levels of autophagic flux. (E) MEFs were treated with BSA control or 
PA (0.25 mM) for 4 hours with or without the presence of BAPTA-AM (10 μM). 
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3.1.6 PKC-α is involved in the induction of autophagy in PA-treated cells 
After establishing the role of classical PKCs in PA-induced autophagy, we then tried to 
identify the member of PKC within the classical group that is responsible for autophagy 
induction in PA-treated cells. There was indeed enhanced phosphorylated PKC-α in PA-
treated cells comparing to the BSA-treated cells, while no evident changes in 
phosphorylation of PKC-α was observed in the OA-treated cells (Fig. 14A). As expected, 
a similar increase was found in cells treated with 12-O-tetradecanoylphorbol-13-acetate 
(TPA), which is known to activate members of the PKC family including PKC-α 
(Gschwendt et al., 1991). To further confirm the results obtained above, we further 
examined the activation of PKC-α during PA-treatment by measuring the 
phosphorylation levels of tyrosine residues from immuno-precipitated PKC-α protein. As 
shown in Figure 14B, we observed that PKC-α tyrosine phosphorylation level was 
significantly increased after PA treatment compared to the BSA treated cells. A similar 
increase in tyrosine phosphorylation was observed in the TPA-treated cells (Fig. 14B). 
Consistently, PA has a much stronger effect than OA in enhancing the PKC-α tyrosine 
phosphorylation level while this effect was comparable to the effect of TPA treatment 
(Fig. 14B). Finally, we confirmed the involvement of PKC-α in PA-induced autophagy 
via siRNA knock-down of PKC-α. An increase in autophagic flux was observed in the 
PA-treated cells that were transfected with the control scrambled siRNA (Fig. 14C). 
However, we observed that the increase in LC3-II conversion and autophagic flux was 
inhibited in the MEFs where PKC-α was knocked-down with the PKC-α siRNA (Fig. 
14C).  There, data presented in this part of our study clearly demonstrates that PKC-α 
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activation is the upstream signaling pathway that is essential for autophagy induction that 








Figure 14. Activation of PKC-α is required for PA-induced autophagy. (A) MEFs were treated with 
BSA, PA (0.25 mM) or OA (0.25 mM) for 4 hours. Cells treated with TPA (100 nM) for 20 minutes were 
used as a positive control for activation of PKC-α. The respective lane intensity was quantified using as a 
fold change to the BSA treatment. (B) MEFs were treated with BSA, PA (0.25 mM) or OA (0.25 mM) for 4 
hours and PKC-α was then immunoprecipitated. TPA (100 nM) was added to the cells for 20 minutes as a 
positive control for PKC- activation. The respective lane intensity was quantified as a fold change to the 
BSA control treatment. (C) PKC-α in MEFs was knocked-down with PKC-α siRNA while the control cells 
were transfected with scramble siRNA as described. The cells were then treated with either BSA or PA 
(0.25 mM) for 4 hours with or without the presence of CQ (10 μM). 
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3.1.7 DGAT1 knock-down does not affect autophagy levels upon OA treatment 
As mentioned earlier, the substrate specificity of DGAT for fatty acyl-CoAs that contain 
the 18C:1 chain derived from OA compared to other fatty acyl-CoAs that have the 16C:0 
chain coming from PA (Coleman and Bell, 1976; Li et al., 2010) could explain why the 
OA-treated MEFs and HepG2 have a much more elevated levels of intracellular TAG 
compared to that of DAG (Fig. 11B and 12B); while in cells treated with PA the 
accumulation of intracellular DAG was more significant than that of the increase in TAG 
levels (Fig. 11A and 12A). There are 2 isoforms of DGAT enzymes that have been 
identified in mammalian cells namely DGAT1 and DGAT2 (Coleman and Mashek, 2011). 
Although both enzymes contribute to TAG synthesis, there may still be functional 
difference between the 2 since Dgat1
-/-
 mice are resistant to diet induced obesity (Smith et 
al., 2000) while Dgat2
-/-
 mice dies shortly after birth (Stone et al., 2004). Previous studies 
have described that knockdown of DGAT1 alone is sufficient to cause an increase in 
DAG levels while inhibiting the formation of TAG (Listenberger et al., 2003; 
Listenberger et al., 2001). To further investigate whether DAG accumulation is indeed 
required for induction of autophagy upon FFAs stimulation, we therefore knocked-down 
DGAT1 in the MEFs as indicated (Fig. 15A). However, we observed only a very slight 
but not significant increase in autophagic levels of the cells treated with OA upon 
DGAT1 knockdown. Such observation thus suggests that both DGAT1 and DGAT2 play 
an important role in the efficient conversion of DAG to TAG in cells upon stimulation by 
exogenous source of PA. Additional experiments consisting of both DGAT1 and DGAT2 
concurrently will be essential to confirm for the role of both enzymes in TAG formation 




Figure 15. OA treatment does not induce autophagy in DGAT1 knockdown MEFs. (A) 
DGAT1 was knocked down in MEFS using DGAT-1 siRNA as described. Scrambled siRNA were 
used as a control for the knock down. Real-Time PCR was then used to determine the DGAT1 
mRNA levels in the MEFs treated with scrambled and DGAT-1 siRNA.  Relative DGAT1 mRNA 
levels were obtained by normalizing to the DGAT1 mRNA levels in the MEFs treated with 
scrambled siRNA (**p<0.01, student’s t-test).  (B) MEFS treated with scrambled siRNA as 
control or DGAT1 siRNA to knock down DGAT-1 protein were treated with either BSA, PA 
(0.25 mM) or OA (0.25 mM) for 4 hours. CQ (10 uM) was added to MEFs together with the 




3.1.8 Autophagy induction protects cell against lipotoxic properties of PA 
In the next part of the study, we aimed to investigate the physiological relevance of PA-
induced autophagy. There have been many studies which have reported that PA is 
cytotoxic and is able to lead to lipoapoptosis upon chronic exposure to cells (Cunha et al., 
2008; Listenberger et al., 2003; Listenberger et al., 2001; Maedler et al., 2001; Malhi et 
al., 2006; Schaffer, 2003). Using phase-contrast microscopy, we first observed that 
treatment with PA up to 24 hours resulted in a significant increase in the number of dead 
cells as compared to the BSA-treated cells (Fig. 16A). This observation was further 
validated using the propidium iodide live cell exclusion assay coupled with flow 
cytometry as shown in Figure 16B - C. Notably, we observed that the addition of CQ 
markedly enhanced cell death induced by PA in both assays (Fig. 16A-C). Furthermore, 
addition of CQ to the BSA treated cells for up to 24 hours did not induce any significant 
decrease in cell viability, suggesting that CQ alone is not cytotoxic to the cells (Fig. 16C). 
Since CQ is known to block autophagy by suppressing the lysosomal function, the 
observations reported thus indicate that PA-induced autophagy may serve as a pro-
survival function to protect against PA-mediated lipotoxicity. To confirm that the above 
observations were not cell type specific, we repeated the treatments on the HepG2 cells. 
Indeed, we observed significant increase in cell death of the PA-treated HepG2 cells 
using both phase-contrast microscopy and PI staining when compared to BSA-treated 
cells (Fig. 16D-E). Furthermore, addition of CQ to the PA-treated HepG2 cells also 
resulted in further increase in cell death compared to those treated with PA alone (Fig. 
16D-E). Therefore the observations in HepG2 cells are in agreement with our conclusion 







Figure 16. Autophagy acts as a cell survival mechanism against lipotoxicity caused by PA. (A) Cell 
morphology observed under a phase contrast microscopy (×200) of MEFs treated with either BSA or PA 
(0.25 mM) for 24 hours with or without the presence of CQ (10 μM). (B) Representative dot-plots of flow 
cytometry data of propidium iodide exclusion test. MEFs treated as described in (A). (C) Quantification of 
the cell viability data from panel B. Data were presented as means ± S.D. of three independent experiments. 
(*p<0.05, **p<0.01, student’s t-test). (D) HepG2 cells were treated with either BSA or PA (0.25 mM) for 
24 hours with or without the presence of CQ (10 μM) and the cell morphology was observed under a phase 
contrast microscopy (×200). (E) Cells were treated with BSA or PA (0.25 mM) with or without the addition 
of CQ (10 μM) for the time points indicated and then subjected to propidium iodide staining. Quantification 
of the cell viability data are presented as means ± S.D. of three independent experiments. (*p<0.05, 
**p<0.01, student’s t-test).  
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To further confirm that autophagy plays a cell survival role in response to PA and to 
investigate the cell death mechanism involved, we compared PA-induced cell death 
between the WT and Atg5 KO MEFs. There were significantly higher levels of the classic 
apoptotic markers, Caspase 3 and PARP cleavage in the PA-treated Atg5 KO MEFs when 
compared to the PA-treated WT MEFs (Fig. 17A). The above observation suggested that 
the cells died via apoptosis upon chronic PA treatment and is in agreement with previous 
results that autophagy plays an important cell survival role in cells during times of 
lipotoxic stress. We then confirmed the above results by knocking down Atg7 in the 
MEFs. As shown in Figure 17B, Atg7 knock-down led to (i) complete suppression of 
LC3-II conversion induced by PA, and (ii) significant increase of apoptotic cell death, 
shown by an increase of both the classic apoptotic markers Caspase 3 and PARP cleavage. 
Similar results were obtained when we repeated the Atg7 knock down experiment on the 
HepG2 cells where we observed the suppression of LC3-II conversion in the Atg7 knock 
down cells coupled to the increased cleavage of Caspase 3 and PARP (Fig. 17C).   
Since our earlier data establish the role of PKC-α in PA-induced autophagy, we 
investigated whether PKC-α knock-down would affect the lipotoxicity of PA. It was 
found that PKC-α knock-down first reduced the LC3-II protein level, being consistent 
with the earlier findings that the general and classical PKC inhibitors are capable of 
inhibiting PA-induced autophagy (Fig. 13A-C). More importantly, PKC-α knock-down 
also markedly enhanced both caspase 3 and PARP cleavage, thus further supporting the 
pro-survival function of autophagy induced by PA (Fig. 17D). Interestingly, we observed 
that reduction of the LC3-II level in PKC-α knock-down was not as effective as Atg7 
knock-down in suppression of autophagy (LC3-II conversion), while the sensitization on 
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PA-induced apoptosis (Caspase 3 and PARP cleavage) was similar or even stronger (Fig. 
17B and D). Such a discrepancy suggests the possibility that PKC-α may also mediate 












Figure 17. Autophagy acts as a cell survival mechanism against lipoapoptosis induced by PA 
treatment. (A) WT and Atg5 KO MEFs were treated with either BSA or PA (0.25 mM) for the indicated 
time points (B) Atg7 was knocked-down with Atg7 siRNA and the cells were treated with either BSA or 
PA (0.25 mM) for the indicated time points. (C) Atg7 in HepG2 cells was knocked-down with Atg7 siRNA 
and the cells were treated with either BSA or PA (0.25 mM) for the indicated time points. (D) PKC-α in 
MEFs was knocked-down with PKC-α siRNA and the cells were treated with either BSA or PA (0.25 mM) 
for the indicated time points. 
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3.2 Critical role of SCD-1 in autophagy regulation via lipogenesis and 
lipid rafts-coupled Akt-FoxO1 signaling pathway 
3.2.1 Elevated levels of lipogenic enzymes and lipid species in the Tsc2
-/-
 MEFs     
In the first part of the study, we have shown that stimulating cells with a lipotoxic 
environment through the addition of exogenous SFAs like PA can lead to the induction of 
autophagy while adding MUFAs such as OA does not affect the autophagic process. 
Therefore in the next part of the study, we set out to investigate how modulation of the 
levels of intracellular FFAs can affect the autophagic process. As described, cells 
deficient in the functional TSC1-TSC2 complex possess a constitutively activated 
MTORC1 signaling pathway that is independent of growth factors regulation and TSC 
patients normally develop multiple benign tumors at multiple organs (Bhaskar and Hay, 
2007; Tee et al., 2002). A constitutively active MTORC1 signaling pathway has been 
shown to result in increased de novo lipogenesis in the cells via increased expression of 
lipogenic enzymes like FASN and SCD-1 which regulates the de novo synthesis of FAs 
in cells  (Duvel et al., 2010; Peterson et al., 2011; Porstmann et al., 2005; Porstmann et al., 




 MEFs as our cellular 
model in this part of the study to investigate how alterations in intracellular levels of 
SFAs and MUFAs can affect the autophagic process in cells with normal versus 
hyperactivated MTORC1 signaling pathway. 
In order to first understand the changes of lipid metabolism downstream of MTORC1, we 










 MEFs when compared to the Tsc2
+/+
 MEFs and a similar trend was observed for 
FASN, although to a much lesser extent (Fig. 18A). The mRNA levels of SCD-1, but not 
that of FASN, were also significantly elevated in the Tsc2
-/-
 MEFs when compared to the 
Tsc2
+/+
 MEFs (Fig. 18B and 18C, respectively). We then proceeded to compare the levels 




 MEFs after lipid extraction. For 
the neutral lipids that were measured, the TAG levels in the Tsc2
-/-
 MEFs were more than 
2 fold higher than that in the Tsc2
+/+
 cells (Fig. 18D), while the DAG levels were similar 
in both cell types (Fig. 18E). On the other hand, the total cholesterol levels in the Tsc2
-/-
 
MEFs were almost 1.7 fold higher than that in the Tsc2
+/+
 cells (Fig. 18F), while no 
significant difference was observed for the cholesteryl esters (CE) (Fig. 18G). We then 
went on to measure and compare the levels of glycerophospholipids in the two different 
cell types. Of all the glycerophospholipids measured, we observed significantly higher 
levels of phosphatidylcholine (PC), phosphatidylinositol (PI), phosphatidylglycerol (PG) 
and PE in the Tsc2
-/-
 MEFs (Fig. 19A-D, respectively), while a similar trend was found 
for phosphatidic acid (PhA) and phosphatidylserine (PS), although not statistically 
significant (Fig. 19E and 19F, respectively). Thus the data from this part of our study 
suggest that in Tsc2
-/-
 MEFs with constitutive activation of MTORC1 there is increased 
expression of enzymes involved in de novo lipogenesis, leading to increased levels of 
various lipid species. This result is generally in agreement with previous studies that 
MTORC1 signaling pathway is a positive regulator for genes involved in de novo 








Figure 18: Enzymes involved in de novo lipogenesis pathways and neutral lipids are elevated in the 
Tsc2
-/-




 MEFs. (B and C) mRNA 
levels of (B) SCD-1 and  (C) FASN were measured by qRT-PCR and presented as the mean ± SD relative 
to the levels in Tsc2
+/+
 MEFs from three independent experiments (*p<0.05, student’s t-test). (D-G) Lipid 




MEFs and the total levels of (D) triacylglycerol (E) 
diacylglycerol, (F) cholesterol and (G) cholesterol esters were measured as described and presented as the 
mean ± SD relative to the levels in Tsc2
+/+
 MEFs from  three independent experiments (**p<0.01, student’s 









Figure 19: Various groups of glycerophospholipid species are elevated in the Tsc2
-/-
 MEFs. Lipid was 




MEFs and the total levels of (A) PC (B) PI (C) PG (D) PE (E) PhA 
and (F) PS were measured as described in the experimental procedure and presented as the mean ± SD 
relative to the levels in Tsc2
+/+
 MEFs from three independent experiments (*p<0.05, **p<0.01, student’s t-









Earlier studies have demonstrated that elevated SCD-1 expression and enzymatic activity 
is important for the proliferation of cancer cells (Minville-Walz et al., 2010; Morgan-
Lappe et al., 2007; Scaglia et al., 2009). Furthermore, there is evidence linking loss of 
SCD-1 activity to the down-regulation of the PI3K-Akt-MTOR signalling pathway in 
different cancer cells (Fritz et al., 2010; Igal, 2010; Nashed et al., 2012). As the 
MTORC1 signaling pathway acts as a negative regulator of autophagy, we went on to 





 MEFs. Interestingly, inhibition of SCD-1 activity with a small 
molecule inhibitor CAY-10566 (CAY) for 24 hours resulted in an increase in LC3-I to 
LC3-II conversion in the Tsc2
-/-
 MEFs, suggesting an increase in autophagic activity (Fig. 
20A). This observation was further supported by the increase in the formation of GFP-
LC3 puncta in the CAY-treated Tsc2
-/-
 MEFs with transient transfection of the GFP-LC3 
plasmid (Fig. 20B). We further determined the autophagic flux by using CQ to block 
autophagosome degradation. As shown in Figure 20C, addition of CQ markedly 
increased LC3-II conversion in the Tsc2
-/-
 MEFs treated with the SCD-1 inhibitor. To 
show that the increase in autophagic flux translated into an increase in the degradative 
ability of the autolysosomes, we next used a lysosomal substrate DQ-BSA. Inhibition of 
SCD-1 with CAY was able to increase the degradation of DQ-BSA in the Tsc2
-/-
 MEFs as 
evidenced by the increase in fluorescence intensity due to the cleavage of the DQ-BSA 
substrate (Fig. 20D). On the other hand, Tsc2
-/-








Figure 20: Inhibition of SCD-1 enzymatic activity by CAY induces autophagy that is independent of 
MTORC1 inhibition in the Tsc2
-/-




 MEFs were treated with CAY (10 µM) 





 MEFs were transfected with the GFP-LC3 plasmid and subjected to treatment with CAY (10 
µM) for 24 hours. GFP-LC3 punctas formation was then visualized using confocal microscopy and images 




 MEFs were treated with CAY (10 µM) 





 MEFs were treated with CAY (10 µM) for 24 hours. DQ
TM
 Red BSA (10 µg/ml) 





 MEFs were either transfected with scrambled or SCD-1 siRNA as described and the 
cells were treated with or without CQ (10µM) for 24 hours to determine the levels of autophagic flux.    
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shown to have lower basal levels of autophagy compared to the Tsc2
+/+
 MEFs due to its 
relatively high levels of MTORC1 activity (Ng et al., 2011). Consistently, we observed 
increased number of GFP-LC3 puncta and higher DQ-BSA fluorescence intensity in the 
non-treated Tsc2
+/+
 MEFs when compared to the corresponding Tsc2
-/-
 MEFs (Fig. 20A-
D).  
In order to confirm the data from the chemical inhibitor, we next transiently knocked 




 MEFs and investigated the 
changes in autophagic flux. Consistently, knockdown of SCD-1 led to increased 
autophagic flux only in the Tsc2
-/-
 MEFs (Fig. 20E).  Interestingly, SCD-1 inhibition did 




 MEFs, while total TAG levels 
were decreased significantly only in the CAY-treated Tsc2
-/-
 MEFS when the lipids from 
the treated cells were extracted and subjected to mass spectrometry analysis (Fig. 21A-B). 
Further analysis of the compositions of the neutral lipids in cells treated with CAY 
showed similar decrease in unsaturated fatty acids and increase in saturated fatty acids in 
both cells (Fig. 21C-D). These results thus suggest that the small molecule inhibitor CAY 





MEFs and the differences observed with autophagy induction are not due to differential 



















Figure 21: Inhibition of SCD-1 activity by CAY results in decrease of unsaturated fatty acid chains in 




MEFs were treated with CAY (10 µM) for 24 hours. Cells were then 
subjected to lipid extraction and the (A) total DAG levels and (B) total TAG levels were measured. The 
same samples were also analyzed for (C) composition of DAG species and (D) the composition of TAG 
species. Data is presented as the mean ± SD relative to the levels of control cells from three independent 
experiments (*p<0.05, **p<0.01, student’s t-test).    
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To further verify the involvement of TSC2 in determining the susceptibility to SCD-1 
inhibition, we utilized a pair of Tsc2
-/-
 MEFs that were stably reconstituted with either an 
empty vector (+EV) or TSC2 (+TSC2) (Huang et al., 2008). As expected, the cells 
reconstituted with TCS2 protein had decreased levels of MTORC1 activity as evidenced 
by the lower levels of p-S6 compared to the cells reconstituted with the empty vector (Fig. 
22A). Furthermore, the expression of SCD-1 protein levels was decreased in the TSC2 
reconstituted cells, being consistent with the earlier finding for the higher level of SCD-1 
expression in Tsc2
-/-
 MEFs (Fig. 20A and Fig. 22A). Consistently, upon treatment with 
the SCD-1 inhibitor, there was no induction of autophagy observed in the cells 
reconstituted with TSC2 protein (Fig. 22B). Therefore, data from this part of our study 
demonstrate that inhibition of the enzymatic activity of SCD-1 is able to selectively 












Figure 22: Induction of autophagy by inhibition of SCD-1 enzymatic activity can be rescued with 
reconstitution of TSC2 protein into Tsc2
-/-
 MEFs. (A) Tsc2
-/-
 MEFs reconstituted with TSC2 protein 
(+TSC2) or an empty vector (+EV) were treated with CAY (10 µM) for 24 hours. (B) Tsc2
-/-
 MEFs 
reconstituted with TSC2 protein (+TSC2) or an empty vector (+EV) were treated with CAY (10 µM) alone, 
CQ (10 µM) or concurrently with both inhibitors for 24 hours for measurement of autophagic flux.  
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3.2.3 Inhibition of SCD-1 blocks phosphorylation and activation of Akt without 
affecting MTORC2 
The earlier data showed that CAY failed to change the phosphorylation levels of S6 




 MEFs (Fig. 21A, Fig. 22A-B), suggesting that 
autophagy induced by SCD-1 inhibition in the Tsc2
-/-
 MEFs was independent of 
MTORC1 regulation. However, we did observe a time-dependent decrease of 
phosphorylation of Akt-S473 in the Tsc2
-/-
 MEFs, but not in the Tsc2
+/+
 cells when SCD-
1 activity was inhibited (Fig. 23A). It is known that MTORC2 is the kinase responsible 
for phosphorylation of Akt-S473 (Sarbassov et al., 2005). Moreover, it was recently 
reported that disruption of lipid homeostasis in cells could affect the association between 
MTOR and Rictor, a vital component of MTORC2 and thus inhibit Akt activation (Zhang 
et al., 2012). Therefore, we examined whether MTORC2 assembly was impaired 
following inhibition of SCD-1 enzymatic activity. As shown in Figure 23B, the 
interactions of MTOR with Raptor or Rictor were not affected upon inhibition of SCD-1 




 MEFs, suggesting that both MTORC1 and 
MTORC2 formation was not affected adversely by SCD-1 inhibition. In contrast, 
rapamycin markedly reduced the interaction between MTOR and Raptor or Rictor, being 
consistent with an earlier report that prolonged treatment with rapamycin disrupted both 
MTORC1 and MTORC2 formation (Sarbassov et al., 2006). To further confirm the effect 
of SCD-1 inhibition on MTORC2, we detected MTORC2 formation by co-
immunoprecipitation with an antibody against Rictor. Similarly, association of Rictor 
with essential components of MTORC2 including MTOR and Sin-1 proteins were not 
affected upon inhibition of SCD-1 enzymatic activity in both cell types (Fig. 23C). 
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Phosphorylation of N-myc downstream-regulated gene (NDRG) protein at T346 has also 
been shown to be MTORC2-dependent (Garcia-Martinez and Alessi, 2008). Consistently, 
CAY did not alter the phosphorylation of T346 on NDRG protein in either the Tsc2
-/-
 
MEFs (Fig. 23D). Therefore, it is believed that neither the kinase activity of MTORC2 
nor the complex assembly was affected by inhibition of SCD-1 enzymatic activity. We 
further investigated whether phosphorylation of T308 on the Akt protein mediated by 
PDK-1 was affected by inhibition of SCD-1 enzymatic activity in the Tsc2
-/-
 cells. Indeed 
we observed that CAY caused a loss of phosphorylation at T308 on Akt protein in the 
Tsc2
-/-
 MEFs, but not in the Tsc2
+/+
 cells, being consistent with the trends that were 
observed in the changes of phosphorylation of Akt-S473 (Fig. 23D). To further confirm 
the effects of loss of SCD-1 activity on Akt activation, we investigated the 
phosphorylation on Akt with SCD-1 knockdown using siRNA. In agreement with the 
results from the chemical inhibitor, loss of SCD-1 resulted in decrease of phosphorylation 
at both S308 and T473 sites on Akt protein only in the Tsc2
-/-
 MEFs (Fig. 23E). To 
further confirm the above conclusions, we then tried to inhibit SCD-1 activity in the cells 
reconstituted with TSC2 protein to verify the effects of SCD-1 inhibition on MTORC2 
formation. Consistently, we also observed that treatment with CAY did not affect the 
formation of MTORC2 in the cells reconstituted with TSC2 protein (Fig. 24A-B). 
Furthermore, CAY treatment also did not affect the phosphorylation of NDRG protein on 
T346 in the TCS2 reconstituted MEFs (Fig. 24C). Notably, TSC2 protein reconstitution 
was able to prevent the loss of phosphorylation on the T308 and S473 sites of the Akt 
protein by SCD-1 inhibition (Fig. 24C). These observations thus help to confirm that that 
107 
 
inhibition of Akt protein phosphorylation occurred only in cells deficient for TSC2 
















Figure 23: Inhibition of SCD-1 enzymatic activity does not affect MTORC2 formation and activity 




 MEFs were treated with CAY (10 µM) for the 





 MEFs were treated with CAY (10 µM) or rapamycin (100 nM) for 24 hours. Co-





 MEFs were treated with CAY (10 µM) for 24 hours. Co-immunoprecipitation using an Anti-Rictor 




 MEFs were treated with 





 MEFs were either transfected with scrambled or SCD-1 siRNA as described before the cells were 













Figure 24: Inhibition of Akt protein activation in the Tsc2
-/-
 MEFs can be rescued by the 
reconstitution of TSC2 protein into the Tsc2
-/-
 MEFs. (A) Reconstituted Tsc2
-/-
 MEFs (+TSC2 and +EV) 
were treated with CAY (10 µM) or rapamycin (100 nM) for 24 hours. Co-immunoprecipitation using an 
anti-MTOR antibody was then carried out. (B) Reconstituted Tsc2
-/-
 MEFs (+TSC2 and +EV) were treated 
with CAY (10 µM) for 24 hours. Co-immunoprecipitation using an Anti-Rictor antibody was then carried 
out. (C) Reconstituted Tsc2
-/-
 MEFs (+TSC2 and +EV) were treated with CAY (10 µM) for 24 hours and 








It has previously been reported that Akt is recruited to plasma membrane for activation 
and this process requires the presence of functional lipid rafts (Calay et al., 2010; Zhuang 
et al., 2002). Therefore, we then went on to examine the role of lipid rafts in Akt 
activation caused by SCD-1 inhibition in the Tsc2
-/-
 MEFs by separating the treated cells 
into detergent resistant fractions (DRF) containing lipid rafts and the detergent soluble 
fractions (DSF). Firstly, we observed that SCD-1 inhibition by CAY led to a much more 
evident reduction of total Akt protein levels in the DRF containing lipid rafts in the Tsc2
-
/-
 MEFs in comparison to the Tsc2
+/+
 cells (Fig. 25A). Methyl-β-cyclodextrin (MBCD) 





 MEFs treated with it showed depletion of total Akt protein from the 
DRF (Fig. 25A). Secondly, we also observed that Tsc2
-/-
 MEFs contained much lower 
level of caveolin-1 protein (Fig. 25A-B). Caveolin-1 is one of the key components in  
lipid rafts (Simons and Toomre, 2000) and notably, the caveolin-1 protein level was 
restored in the TSC2 reconstituted cells (Fig. 25B), indicating the possible functional 
connection between TSC2 and caveolin-1. Meanwhile, CAY increased caveolin-1 level 
in the detergent soluble fractions (DSF) of the Tsc2
-/-





 MEFs are more susceptible to the disruption of lipid raft upon 
inhibition of SCD-1 (Fig. 25A). In contrast, MBCD treatment exerted similar effects in 
both cells (Fig. 25A). Next, we visualized lipid rafts by using the fluorescence tagged 
Cholera Toxin Subunit B (CTxB) which binds to lipid raft enriched GM1 ganglioside 
(Yamaguchi et al., 2009). As shown in Figure 25C, Tsc2
-/-
 MEFs had a much weaker 
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basal fluorescence in comparison to the Tsc2
+/+
 cells, being consistent with the earlier 
observations that Tsc2
-/-
 MEFs possess lower level of caveolin-1 protein (Fig. 25A-B).  
Treatment with CAY further decreased the CTxB staining in the Tsc2
-/-
 MEFs, while no 
significant changes were observed in the Tsc2
+/+
 cells (Fig. 25C). Consistently, MBCD 
was able to effectively disrupt CTxB staining in both cell types with similar efficacy and 
cholesterol is known to be an essential component of lipid rafts (Simons and Toomre, 
2000). Accordingly, the loss of lipid raft staining could be rescued by cholesterol 
replenishment in the Tsc2
-/-
 MEFs treated with CAY, suggesting that lipid rafts disruption 
caused by SCD-1 inhibition is likely mediated by cholesterol depletion (Fig. 25C). To 
confirm, we then measured the intracellular cholesterol levels and found that treatment 
with CAY caused a significant decrease (about 30%) in cholesterol levels in the Tsc2
-/-
 
MEFs, while no changes were found in the Tsc2
+/+
 cells (Fig. 25D). Interestingly, other 
lipid components of lipid rafts including sphingolipids like sphingomyelin and ceramide 
were equally affected by CAY treatment in both cell types (Fig. 25E-F respectively).  
Since we observed a significant decrease in cholesterol levels in the Tsc2
-/-
 MEFs upon 
SCD-1 inhibition (Fig. 25D), we therefore decided to further investigate the effects of 
cholesterol repletion on the CAY treated Tsc2
-/-
 MEFs. Indeed, cholesterol repletion was 
able to prevent the loss of Akt protein from the DRF caused by MBCD treatment proving 
that functional lipid raft is required for Akt recruitment (Fig. 26A). More importantly, the 
loss of Akt protein from the DRF of the Tsc2
-/-
 MEFs caused by CAY could be reversed 
significantly by cholesterol replenishment (Fig. 26A), suggesting that the loss of Akt 
protein from the DRF after SCD-1 inhibition is due to disruption of lipid rafts on the 














Figure 25: Inhibition of SCD-1 enzymatic activity disrupts lipid rafts and reduces Akt recruitment to 
plasma membrane in Tsc2
-/-




 MEFs were treated with either CAY (10 µM) 
for 24 hours or MBCD (5 mM) for 2 hours. The DSF and DRF were then separated as described. (B) Basal 




 MEFs and the reconstituted Tsc2
-/-
 MEFs (+TSC2 




 MEFs were treated with CAY (10 µM) for 24 hours or MBCD (5 mM) 
for 2 hours. Water soluble cholesterol (CHO, 15 µg/ml) was added to a set of CAY treated cells for the last 





MEFs were treated with CAY (10 µM) for 24 hours. Lipid extraction was 
carried out and the total levels of (D) cholesterol, (E) sphingomyelin and (F) ceramides were measured as 
described and presented as the mean ± SD relative to the levels of control cells from three independent 
experiments (**p<0.01, student’s t-test).  
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replenishment partly restored phosphorylation of Akt (T308 and S473 sites) in Tsc2
-/-
 
MEFs treated with CAY (Fig. 26B). Finally, we tested the changes of autophagic flux in 
Tsc2
-/-
 MEFs with either cholesterol repletion. As shown in Figure 26C, cholesterol 
repletion indeed reduced the autophagic flux level measured by the LC3-II level in Tsc2
-/-
 
MEFs treated with CAY, without affecting MTORC1 activity. We further tried to 
investigate the effects of supplementing the medium with OA which is one of the major 
products of SCD-1 catalyzed desaturation process. We observed that similar to 
cholesterol repletion, the addition of OA to CAY treated Tsc2
-/-
 MEFs was able to 
prevent total loss of phosphorylation on T308 and S473 sites of the Akt protein when 
compared to the cells treated with CAY alone (Fig. 26D). Furthermore, the increase in 
autophagic flux that was observed in cells treated with CAY alone could also be inhibited 
when the medium was supplemented with OA (Fig. 26E).  Taken together, the data from 
this part of our study thus suggest that Akt protein recruitment to the lipid rafts is 
impaired during inhibition of SCD-1 activity due to disruption of lipid rafts formation. 
Furthermore, the loss of cholesterol or unsaturated fatty acid production caused by SCD-1 
inhibition may contribute to the disruption of lipid rafts and impaired Akt activation and 















 Figure 26: Repletion of cholesterol or OA prevents autophagy induction in SCD-1 inhibited cells. (A) 
Tsc2
-/-
 MEFs were treated with either CAY (10 µM) for 24 hours or MBCD (5 mM) for 2 hours. Water 
soluble cholesterol (CHO, 15 µg/ml) was added concurrently to the treated cells for the last 2 hours as a 





MEFs were treated with either CAY (10 µM) for 24 hours or water-soluble cholesterol (CHO, 15 µg/ml) 
for 2 hours.  Water soluble cholesterol (CHO, 15 µg/ml) was added concurrently to CAY treated cells for 




 MEFs were treated as described in 





 MEFs were treated with CAY (10 µM) alone, OA (200 µM) alone or concurrently with both for 
24 hours and cells were collected for immunoblot analysis. (E) Tsc2
-/-
 MEFs were treated as described in 




3.2.5 Autophagy induction in the Tsc2
-/-
 MEFs upon SCD-1 inhibition is FoxO1-
dependent  
The results that have been reported thus far suggest that autophagy induction by the 
inhibition of SCD-1 enzymatic activity is dependent on Akt, but not MTORC1. 
Downstream substrates of Akt include the family of FoxO transcription factors, some of 
which have been implicated in autophagy induction (Sengupta et al., 2009; Xu et al., 
2011; Zhao et al., 2010; Zhou et al., 2012). To further investigate the involvement of Akt-
FoxO1 signaling axis in autophagic induction caused by inhibition of SCD-1 activity, we 
then transfected the Tsc2
-/-
 MEFs with the constitutively active myristoylated form of Akt 
(Myr-Akt) (Murga et al., 1998). Transfection of Myr-Akt into the Tsc2
-/-
 MEFs had no 
effect on the p-S6 levels, being consistent with the notion that regulation of MTOR 
activity in these cells is independent of Akt activity (Fig. 27A). CAY treatment in the 
Tsc2
-/-
 MEFs led to loss of phosphorylation of S473 on Akt and also T24 on FoxO1 only 
in the pcDNA transfected control cells, but not in cells with that over-expressed Myr-Akt 
(Fig. 27A). Akt is responsible for the phosphorylation of T24 on FoxO1 and this 
phosphorylation has been shown to inhibit the transcriptional activity of FoxO1 
(Burgering and Kops, 2002). Consistently, over-expression of Myr-Akt prevented the loss 
of phosphorylation of S473 on Akt and subsequently T24 on FoxO1 upon inhibition of 
SCD-1 activity (Fig. 27A). Furthermore, Myr-Akt expression prevented the increase of 
autophagic flux induced by CAY in the Tsc2
-/-
 MEFs (Fig. 27A). Thus our results support 
a notion that autophagy induction caused by SCD-1 suppression in Tsc2
-/-
 MEFs could be 
mediated by the activation of the FoxO1 transcription factor downstream of Akt 








Figure 27: Activation of FoxO1 is required for autophagy induction caused by SCD-1 inhibition in 
the Tsc2
-/-
 MEFs. (A) Tsc2
-/-
 MEFs were transfected with either pcDNA as control or HA-Myr-Akt as 
described and the cells were then treated with CAY (10 µM) alone, CQ (10 µM) alone or concurrently with 




 MEFs were treated 
with CAY (10 µM) for 24 hours and then the cytosol and nuclear fraction was separated as described. (C) 
Reconstituted Tsc2
-/-
 MEFs (+TSC2 and +EV) were treated with CAY (10 µM) for 24 hours and the cytosol 




nucleus. Consistently, CAY increased accumulation of FoxO1 protein in the nuclear 
fraction of Tsc2
-/-
 MEFs, but not in the Tsc2
+/+
 cells (Fig. 27B). Consistently, FoxO1 
nuclear translocation was reversed by the reconstitution of TSC2 protein (Fig. 27C).  
Since FoxO1 can act as a transcription factor after it is has translocated into the nucleus, 
we next tried to investigate whether nuclear translocation of FoxO1 after SCD-1 





 MEFs with the two different luciferase constructs, WT FoxO1-luc and 
FoxO1(mut 1+2)-luc before subjecting the cells to CAY treatment. Indeed, we observed a 
significant increase in the FoxO1 transcriptional activity in the CAY treated Tsc2
-/-
 MEFs 
as measured by the luciferase assay (Fig. 28A). As expected, there was no increase in 
luciferase activity in the cells transfected with the FoxO1(mut 1+2)-luc construct which 
contains mutations in the consensus sequence recognized by FoxO1 (Al-Mubarak et al., 
2009). Our data thus further support the notion that suppression of SCD-1 by CAY 
increases FoxO1 transcriptional activity. In agreement with previous results where 
phosphorylation of FoxO1 was not affected in the CAY Tsc2
+/+
 MEFs, we observed no 
changes in the luciferase activity of the CAY treated Tsc2
+/+
 MEFs that were transfected 
with the WT FoxO1-luc construct (Fig. 28A). FoxO proteins have been previously 
reported to control the expression of genes that are involved in controlling the autophagic 
process (Sengupta et al., 2009; Xu et al., 2011; Zhao et al., 2010; Zhou et al., 2012). 
Therefore we then went on further to examine the mRNA levels of some FoxO1 target 




 MEFs treated with CAY. In particular, we observed 
significant increases in mRNA levels of genes like ATG4, ATG12, BECLIN1, BNIP3, 
BNIP3L, LC3B and VPS34 in CAY-treated Tsc2
-/-
 MEFs (Fig. 28B), while no significant 
126 
 
changes in the mRNA levels of these genes were observed in the Tsc2
+/+
 MEFs when 
treated with the same inhibitor (Fig. 28C). Moreover, a known FoxO1 protein inhibitor 
AS1842856 (AS) (Nagashima et al., 2010) was able to significantly suppress the 
activating effect of CAY on the expression of the target genes, except for BNIP3 and 
BNIP3L (Fig. 28B). Consistently, AS was able to block the increase in autophagic flux 
caused by CAY treatment in the Tsc2
-/-
 MEFs (Fig. 28D, left panel), while no changes in 
the autophagic flux of the Tsc2
+/+
 MEFs was found (Fig. 28D, right panel). To support 
the data from the FoxO1 chemical inhibitor, we carried out experiments with FoxO1 
knock-down using siRNA in the Tsc2
-/-
 MEFs. As shown in Fig. 28E, FoxO1 knockdown 
effectively reduced the autophagic flux caused by CAY treatment. Therefore, the above 
results provide strong evidence suggesting that autophagy induction in CAY-treated Tsc2
-
/-
 MEFs is dependent on activation of FoxO1 downstream of impaired Akt activation due 











Figure 28: Activation of FoxO1 transcriptional activity is required for autophagy induction upon 
SCD-1 inhibition in Tsc2
-/-




 MEFs were transfected with either WT FoxO1-
luc or FoxO1(mut 1+2)-luc vector together with Renilla luciferase vector as internal control as described. 
The cells were then treated with CAY (10 µM) for 24 hours before the luciferase activity was determined. 
Relative luciferase activity was presented as the mean ± SD relative to the levels of the control cells from 
three independent experiments (**p<0.01, student’s t-test). (B) Tsc2-/- MEFs were treated with CAY (10 
µM) alone, AS (250 nM) alone or concurrently with both inhibitors for 24 hours. mRNA levels of various 
genes involved in the autophagy process were then measured by qRT-PCR and presented as the mean ± SD 
relative to the levels in the control cells from three independent experiments (*p<0.05, **p<0.01, student’s 
t-test) (C) Tsc2
+/+
 MEFs were treated with CAY (10 µM) for 24 hours and mRNA levels of various genes 
involved in the autophagy process was then measured by qRT-PCR and presented as the mean ± SD 





were treated with CAY (10 µM) alone, AS (250 nM) alone or concurrently with both inhibitors for 24 
hours with or without the presence of CQ (10 µM) to measure the autophagic flux. (E) Scrambled or FoxO1 
siRNA was transfected into Tsc2
-/-
 MEFs as described and the cells were then treated with CAY (10 µM) 






 MEFs are more sensitive to SCD-1 inhibition and autophagy promotes 
cell survival  
SCD-1 enzymatic activity and the MUFAs it produces have been shown to be critical for 
cell proliferation and suppression of SCD-1 is cytotoxic to numerous cancer cell types 
that have been tested (Igal, 2010; Scaglia et al., 2005; Scaglia and Igal, 2005). Here we 




 MEFs. As shown in 
Figure 29A, Tsc2
-/-
 MEFs were found to be much more sensitive to CAY-mediated 
cytotoxicity than Tsc2
+/+
 MEFs.  Furthermore, addition of CQ together with CAY 
resulted in further increase cell death (Fig. 29A), suggesting that autophagy is a cell 
survival mechanism in the Tsc2
-/-
 MEFs. Consistent results were obtained when cell 
viability was quantified using propidium iodide live cell exclusion (Fig. 29B). The above 
results are in agreement with previous studies that cells with hyperactivated growth 
signaling pathways are more dependent on de novo lipogenesis for survival and thus more 
susceptible to stress factors (Hess et al., 2010; Igal, 2010; Menendez and Lupu, 2007). 
We further examined the form of cell death induced by SCD-1 inhibition. There was an 
evident increase of both caspase 3 and PARP cleavage, which are all classical markers of 
apoptosis, upon treatment with CAY for up to 48 hrs (Fig. 29C). Finally, a long term 
colony formation assay was carried out to investigate the long term effect of SCD-1 
inhibition. CAY treatment significantly decreased the long term cell viability of the Tsc2
-
/-
 MEFs and the effects could be significantly enhanced by addition of CQ, while Tsc2
+/+
 
MEFs were much less susceptible to the treatment of CAY and/or CQ (Fig. 29D). Taken 
together, results from this part of our study suggest that autophagy mediated by SCD-1 











 MEFs are more susceptible to cell death induced by SCD-1 inhibition and 




 MEFs were treated with CAY (10 
µM) alone, CQ (10 µM) alone or with both inhibitors concurrently for 48 hours. The cell morphology was 




 MEFs were 
treated as described in (A) above and cell viability was quantified using the propidium iodide live cell 
exclusion assay. The results are presented as the mean ± SD from three independent experiments (*p<0.05, 
**p<0.01, student’s t-test) (C) Tsc2+/+ and Tsc2-/- MEFs were treated with CAY (10 µM) for 24 and 48 




 MEFs were 
treated as described in (A) and then re-plated into 6-well plates for the long term cologenic survival assay.  
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4. General Discussion and Conclusions 
4.1 Autophagy induction in cells by PA but not OA   
At present, it is known that autophagy is able to regulate lipid metabolism through 
lipophagy (Settembre et al., 2013; Singh et al., 2009a), while it is still controversial 
whether lipid species like FFA can regulate autophagic activity. In this study we provide 
evidence showing that autophagy can be induced by the SFA, PA, but not by the MUFA, 
OA (Fig. 6 and 7). Our findings are generally consistent with earlier reports that FFA 
such as PA is capable of inducing autophagy in pancreatic ß-cells and also a variety of 
cancer cell lines (Choi et al., 2009; Ebato et al., 2008; Shen et al., 2012). On the other 
hand, it has been reported that both PA and OA treatment prevented fusion of 
autophagosome and lysosome and thus inhibits autophagy (Koga et al., 2010). Another 
recently published paper reported that only OA but not PA was capable of inducing 
autophagy in hepatocytes (Mei et al., 2011). There are several possible explanations for 
the conflicting results that have been reported so far. One possibility is that the effects of 
different FFAs like PA and OA on autophagy are tissue and cell type specific. 
Furthermore, other factor such as concentration and duration of FFAs, as well as the 
concentration of glucose present in the medium have been found to be responsible for 
different outcomes observed (Komiya et al., 2010; Las et al., 2011; Martino et al., 2012; 
Mei et al., 2011; Shen et al., 2012). More importantly, the FFAs that were used for 
treatment in vitro need to be conjugated to fatty acid free BSA in order for them to be 
taken up by the cells. However, detailed review of the literature on the methods used for 
preparation of the BSA-FFA complexes reveal that there are drastic differences in the 
ways these complexes are prepared, and this may be one of the major factors resulting in 
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the conflicting effects regarding the abilities of FFAs to induce or inhibit autophagy 
(Choi et al., 2009; Las et al., 2011; Martino et al., 2012; Mei et al., 2011; Singh et al., 
2009a). Throughout our study, we have prepared our fatty acid complexes according to a 
well-established method that has been used in many other studies (Listenberger and 
Brown, 2007; Listenberger et al., 2003; Listenberger et al., 2001). Furthermore, we have 
consistently treated the cells in FBS-free medium to make sure that no other lipids are 
present in the medium used for culturing of the cells and ensure that the effects we have 
observed on autophagic activity is truly due to PA treatment.    
4.2 De Novo Ceramide biosynthesis is not involved in PA-induced 
autophagy  
In the first part of the study, we also attempted to identify the molecular mechanisms 
underlying PA-induced autophagy, with several important findings. Firstly, although an 
increase in total ceramide levels were observed in the PA treated cells, this increase was 
minimal and not statistically significant (Fig. 10A). Furthermore, we conclusively 
excluded the involvement of ceramides in PA-induced autophagy, as the inhibition of 
ceramides synthesis by myriocin or FB1 is unable to block autophagy induction (Fig. 
10B-C). Previous reports have shown that treatment with C2 and C6 ceramides are able to 
induce autophagy in human cancer cells via inhibition of Akt and MTORC1 activity 
(Pattingre et al., 2009; Scarlatti et al., 2004). One possible explanation for this 
discrepancy is the fact that the type of ceramide species generated in their study after 
treatment with the short chain ceramides is different from those accumulated in PA-
treated cells. In our study, the type of ceramide metabolites found in PA-treated cells 
consisted of mainly the Cer(d18:1/16:0) (N-(palmitoyl)-ceramide) species since the main 
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substrate used was PA made up of 16 carbon aliphatic chain. Furthermore, it is important 
to note that the other studies mentioned did not investigate specifically the types of 
ceramide species that were generated intracellularly upon C2 and C6 ceramides treatment 
(Pattingre et al., 2009; Scarlatti et al., 2004). Thus autophagy induction could have been a 
direct response to the short chain ceramides without the cells metabolizing them into the 
long chain ceramide species. Furthermore, another important thing to note is that the 
short chain C2 and C6 ceramides that were used for treatment are not normally present in 
the body under physiological conditions (Pattingre et al., 2009; Scarlatti et al., 2004).  On 
the other hand our observations here are consistent with an earlier report that ceramide 
accumulation only plays a nominal role in affecting cellular homeostasis observed in cells 
treated with PA (Listenberger et al., 2001). In this study, PA treatment induced 
cytotoxicity was independent of ceramide synthesis, thus suggesting that ceramide 
accumulation upon PA treatment does not play a significant role in the subsequent 
cellular responses (Listenberger et al., 2001).   
4.3 PA-induced autophagy is independent of MTORC1 regulation and 
mediated by DAG-PKC  signaling pathway  
The other important finding in our study shows that PA-induced autophagy is 
independent of MTORC1 regulation as PA treatment fails to inhibit MTORC1 activity as 
observed by the unaltered levels of p-70S6K and p-S6 (Fig. 8 and 9). It has been reported 
that high levels of FFA leads to constant activation of MTOR activity, a process related 
to the development of diseases such as diabetes and obesity (Muoio and Newgard, 2008). 
Furthermore, it was shown that PA has the ability to induce activation of MTORC1 via 
another member of the PKC family, PKC-δ (Wang et al., 2010). Taken together, it is 
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obvious that PA-induced autophagy is not mediated via suppression of MTORC1 activity. 
As described earlier on, there have been recent studies that have started to propose the 
presence of non-canonical autophagy which is independent of MTORC1 regulation. The 
PKC family has been reported in a number of studies to be able to induce autophagy upon 
different cellular stresses without affecting MTORC1 activity. These studies have 
specifically identified members of the PKC family including PKC-δ and PKC-θ to be 
involved in autophagy induction (Chen et al., 2008; Sakaki and Kaufman, 2008; Sakaki et 
al., 2008; Shahnazari et al., 2010). In our study, we have identified a particular member 
of the classical PKC family, PKC-α as an important mediator in PA-induced autophagy, 
based on the following observations: (i) general and typical PKC inhibitors are able to 
block PA-induced autophagy (Fig. 13); (ii) PA, but not OA, induces PKC-α activation 
(Fig. 14A-B); and (iii) siRNA knock-down of PKC-α significantly reduced PA-induced 
autophagy (Fig. 14C). To our knowledge, this is the first time any study has identified 
PKC-α as an upstream regulator of autophagy. Similar to the recent report highlighting 
the importance of DAG in promoting anti-bacterial autophagy via promoting 
autophagosome formation and activation of PKC-δ (Shahnazari et al., 2010), results from 
our study have also indicated the importance of intracellular DAG. DAG acts as the main 
stimulus for induction of autophagy via activation of PKC-α, based on the common 
understanding that DAG is required for activation of classical PKC (Newton, 2001). 
Previous studies have demonstrated that DGAT, the enzyme responsible for conversion 
of DAG to TAG has a higher specificity for the 18C:1-CoA substrate derived from OA 
compared to the 16C:0-CoA substrate derived from PA (Coleman and Bell, 1976; Li et 
al., 2010) and this could be the reason why OA treatment resulted in more significant 
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increase in total TAG levels but much lesser accumulation of DAG compared to PA (Fig. 
11 and 12).  
At present, we have preliminary data showing that OA treatment after the knock-down of 
DGAT1 can ultimately lead to induction of autophagy as well (Fig. 15). This piece of 
evidence thus suggests that DAG accumulation in the OA-treated cells due to the loss of 
DGAT1 is critical for activating the autophagic process, most probably through activation 
of PKC-α as we have shown in the PA-treated cells. Results from this study also raise an 
interesting possibility that DAG accumulation in the cells has undesirable effects on the 
cellular homeostasis and the induction of autophagy via PKC activation may serve the 
purpose of alleviating such adverse effects. The activation of various members of the 
PKC family by accumulation of intracellular DAG induced by PA treatment has been 
well studied (Benoit et al., 2009; Eitel et al., 2003; Yu et al., 2002). These may help us 
understand the fact that lack of DAG accumulation in OA-treated cells did not lead to 
PKC activation and thus no autophagy induction.  
Future studies are needed to elucidate how PKC-α leads to the induction of autophagy in 
the PA-treated cells. This will involve identifying the downstream targets of PKC-α that 
can lead to autophagy induction. There are many examples of kinases like AMPK that 
activates autophagy by phosphorylating and activating ULK1 (Egan et al., 2011; Kim et 
al., 2011) and JNK that phosphorylates Bcl-2 to induce autophagy by preventing its 
interaction with Beclin-1 (Wei et al., 2008a; Wei et al., 2008b). Thus PKC-α could also 
be acting as a kinase for some protein that is critical for autophagic activity. Furthermore, 
we will have to investigate the intracellular localization of the accumulated DAG upon 
PA and OA treatment. This would enable us to find out whether the accumulated DAG 
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can be found on the autophagosome membrane as a way of promoting autophagosome 
formation as has been shown in the previous study depicting the role of DAG in anti-
bacterial autophagy (Shahnazari et al., 2010). As shown in our study, the activation of 
PKC-α  is dependent on DAG activation and it will be important to examine whether 
PKC-α is recruited by DAG to locations near the isolation membrane where it can exert 
its kinase activity on substrates that will lead to enhanced autophagic activity during PA 
treatment. 
4.4 Autophagy is an important cell survival mechanism for cells against 
lipotoxicity caused by PA 
After establishing the role of DAG-PKC in PA-mediated autophagy, we next examined 
the role of autophagy in PA-mediated lipotoxicity. Lipotoxicity has been reported in 
many studies to be the main contributor to the progression of various diseases associated 
with excess lipid accumulation in the body such as obesity, diabetes and the metabolic 
syndrome (Brookheart et al., 2009; Chavez and Summers, 2010).  Common dietary long 
chain saturated FFAs like PA are especially damaging to cells due to their ability to 
induce lipoapoptosis upon chronic treatment with high doses to simulate a lipotoxic 
condition while MUFAs like OA generally have no effects on cell viability (Shimabukuro 
et al., 1998a; Unger, 2003; Unger and Orci, 2002). Several factors such as increased ROS 
production (Piro et al., 2002) and induction of ER stress (Borradaile et al., 2006) upon 
treatment with SFAs have been implicated as the mechanisms of actions leading to 
lipotoxicity. On the other hand, it has been well established that autophagy generally 
serves as an important cell survival mechanism under various stress conditions, such as 
starvation, oxidative stress, DNA damage (Levine and Klionsky, 2004; Mizushima et al., 
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2008). Thus it is no surprise for us to observe an increase in autophagic activity in the 
cells as a way to maintain cellular homeostasis and cell survival in response to the 
cytotoxic PA treatment. Data from this part of our study reveal that PA-induced 
autophagy play a pro-survival function and suppression of autophagy by either CQ or 
knock-down of Atg7 (Fig. 16 and 17 respectively) markedly enhanced PA-induced 
apoptosis. At present, it is still not clear how autophagy protects against PA-mediated cell 
death. One possibility remaining to be tested is that autophagy is involved in degrading 
and clearing the accumulated DAG from the cells via lipases that are present in the 
lysosomes. Earlier study has shown that autophagy plays an important role in lipid 
metabolism by affecting the intracellular levels of  neutral lipids in the cells (Singh et al., 
2009a). Thus, it is possible that autophagy can play a role in regulation of intracellular 
levels of DAG in order to promote cell survival in times of exogenous FFA stress. Such a 
hypothesis is supported by an earlier study that increased TAG accumulation and 
decreased levels of DAG in cells by over-expression of DGAT1 helped to prevent PA-
mediated cell death (Listenberger et al., 2003). Therefore, an important experiment that 
should be done in the future will be to investigate whether excessive DAG accumulation 
in DGAT knocked-down cells upon PA treatment. This is important to prove that DAG 
species are the main cause of cell death in cells during lipotoxicity and thus autophagy 
induction might be a general cellular response to the cytotoxic effects of excess DAG 
accumulation in the cells.  
The results of this part of the study suggest targeting autophagy as potential therapeutic 
strategies for lipotoxicity-related diseases. It will certainly be interesting to investigate 
whether induction of autophagy in disease models like obesity and diabetes can rescue 
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the cells from cell death induced by lipotoxicity. Taken together, as summarized in Figure 
30, here we reveal in the first part of our study a novel mechanism in regulating PA-
induced autophagy during times of lipotoxicity: PA promotes the accumulation of 
intracellular DAG, which in turn activates PKC-α as an upstream signaling mechanism 
for autophagy. Moreover, such inducible autophagy plays an important pro-survival role 
in mitigating PA-induced apoptosis and lipotoxicity.  
 
Figure 30. Summary of the proposed signalling pathways involved in PA-mediated autophagy and its pro-




4.5 Inhibition of SCD-1 activity leads to autophagy induction in the 
Tsc2
-/-
 MEFs     
In the second part of our study, we tried to investigate if modulating the endogenous 
levels of SFAs and MUFAs in cells can lead to changes in autophagic activity. 
Specifically, we tried to use cells with constitutively active MTORC1 signaling pathway 
so as to investigate how cells with high rate of de novo lipogenesis would response to 
changes in endogenous levels of FFAs compared to cells not driven to have high rates of 
lipogenesis. Data from our first part of the study has conclusively shown that stimulation 
with exogenous SFA like PA could lead to autophagy induction via accumulation of 
DAG and activation of PKC- while the MUFA, OA had no such effect. Thus we wanted 
to examine the roles of SCD-1 in lipogenesis and autophagy via suppression of SCD-1 by 
using both a chemical inhibitor and genetic knockdown to increase endogenous SFAs.  
SCD-1 is essential in cells for the de novo synthesis of MUFAs that act as the building 
blocks for all major lipid classes, and play an important role in maintenance of membrane 
fluidity in cells (Hodson and Fielding, 2012; Ntambi and Miyazaki, 2003). Recently, 
SCD-1 has been identified as a potential cancer therapeutic target (Igal, 2010; Morgan-
Lappe et al., 2007).  We confirmed in our cellular model that Tsc2
-/-
 MEFs indeed had 
higher mRNA and protein levels of SCD-1 which contributes to the increased lipogenesis 
in the cells compared to the Tsc2
+/+
 MEFs (Fig. 18 and 19), supporting most of the earlier 
studies on the positive relationship between MTORC1 signaling and increased de novo 
lipogenesis biosynthesis (Duvel et al., 2010; Peterson et al., 2011; Porstmann et al., 2005; 
Porstmann et al., 2008). One key observation from this part of our study is that induction 
of autophagy was observed only in the Tsc2
-/-
 MEFs but not in the Tsc2
+/+
 MEFs when 
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SCD-1 activity was inhibited either with a chemical inhibitor or via siRNA knock-down 
(Fig. 20). This result suggests that cells with high levels of de novo lipogenesis (due to 
constitutive activation of MTORC1) are more susceptible to SCD-1 inhibition. This is in 
contrast to the results from the first part of our study as exogenous PA stimulation 
induces autophagy via accumulation of DAG and activation of PKC- . Furthermore, 





 MEFs upon inhibition of SCD-1 (Fig. 21C and 21D), we did not observe any 
significant changes in DAG levels in these cells (Fig. 21A). The observations here thus 
suggest that we are not able to significantly increase intracellular levels of DAG by 
modulating endogenous levels of SFAs. More importantly, the lack of DAG 
accumulation even in the Tsc2
-/-
 MEFs suggests that some other signaling pathways are 
involved in the regulation of autophagy induction upon SCD-1 inhibition.  
4.6 SCD-1 inhibition contributes to loss of cholesterol and disruption of 
lipid raft structures in the Tsc2
-/-
 MEFs       
One important finding from the second part of our study is that SCD-1 inhibition does not 
affect MTORC1 activity in the Tsc2
-/-
 MEFs (Fig. 20 and 22), suggesting that autophagy 
induction we observed in the Tsc2
-/-
 MEFs was independent of the canonical MTORC1 
regulation. Instead, we demonstrated that SCD-1 inhibition reduced phosphorylation of 
Akt at 2 critical sites, T308 and S473 specifically in the Tsc2
-/-
 MEFs (Fig. 23D-E and 
Fig. 24C). Additionally, we did not observe any disruption of the formation of MTORC2 
which is responsible for phosphorylation of Akt at S473 (Fig. 23B-C and Fig. 24A-B) 
and this suggests to us that maybe the recruitment of Akt to the plasma membrane is 
affected upon SCD-1 inhibition in the Tsc2
-/-
 MEFs.  
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The full activation of Akt in cells has been shown to be dependent on the presence of 
cholesterol-enriched lipid rafts on the plasma membrane. Furthermore, lipid raft 
disruption by the depletion of cholesterol resulted in loss of Akt recruitment to the plasma 
membrane, suppression of Akt activation and eventually cell death (Calay et al., 2010; 
Hill et al., 2002; Zhuang et al., 2002). Lipid rafts are microdomains consisting of 
cholesterol and sphingolipids like ceramide and sphingomyelin that are enriched on the 
exoplasmic leaflet of the membrane bilayer (Simons and Toomre, 2000). Caveolin-1 is an 
important protein in lipid rafts as it forms a subclass of plasma membrane lipid rafts 
termed caveolae by binding to cholesterol (Simons and Ikonen, 2000). Furthermore, 
caveolin-1 is also known to have the ability to regulate cholesterol levels in cells (Parton 
and Simons, 2007). It was previously reported that TSC2 binds to caveolin-1 protein and 
the loss of TSC2 was shown to lead to displacement of caveolin-1 from the plasma 
membrane, leading to decreased lipid raft formation (Jones et al., 2004). In this study, we 
observed lower level of caveolin-1 in the Tsc2
-/-
 MEFs compared to the Tsc2
+/+
 cells, and 
this caveolin-1 level could be restored in the TSC2 reconstituted MEFs (Fig. 25B and Fig. 
26B). Such observations thus indicate that lipid rafts structure and function are impaired 
in Tsc2
-/-
 MEFs. Our lipid profiling data showed that cholesterol depletion and 
subsequent disruption of lipid rafts was only found in the Tsc2
-/-
 MEFs with SCD-1 
inhibition (Fig. 25C-D). Therefore, it is highly possible that the impaired lipid rafts in the 
Tsc2
-/-
 MEFs make these cells more susceptible to SCD-1 inhibition. It has been 
previously shown that the depletion of SCD-1 leads to decreased levels of cholesterol and 
TAG in mice (Miyazaki et al., 2000), while another study also showed that SCD-1 





 MEFs with decreased levels of caveolin-1 are more susceptible to the depletion of 
cholesterol caused by SCD-1 inhibition, leading to further disruption of lipid rafts and 
loss of Akt localization and activation.  
4.7 Activation of FoxO1 transcriptional activity is essential for 
autophagy induction in Tsc2
-/-
 MEFs upon SCD-1 inhibition 
After establishing the critical role of Akt in autophagy induction in Tsc2
-/-
 MEFs 
following SCD-1 inhibition, we further identified FoxO1 transcriptional factor as a key 
downstream target in mediating autophagy observed in cells with SCD-1 inhibition (Fig. 
27 and 28). At present, the exact mechanisms for FoxO-mediated autophagy are still very 
debatable. There are studies showing that increased transcriptional activity of nuclear 
FoxO1 promotes autophagy (Sengupta et al., 2011; Sengupta et al., 2009; Xu et al., 2011). 
Furthermore, another member of the FoxO family, FoxO3a has been implicated in 
regulating the expression of pro-autophagy genes for autophagy induction during a 
variety of stresses, including starvation in haematopoietic stem cells (Warr et al., 2013) 
and lysosomal proteolysis during muscle atrophy upon denervation (Mammucari et al., 
2007; Zhao et al., 2007).  On the other hand, there have been studies demonstrating that 
cytosolic FoxO1 is required for autophagy induction independent of its transcriptional 
activity (Zhao et al., 2010; Zhou et al., 2012). The cytosolic Foxo1 can bind to Atg7 to 
modulate the autophagic process that leads to cell death and tumour suppression (Zhao et 
al., 2010). This is in contrast to our results showing that the transcriptional activity of 
nuclear translocated FoxO1 is crucial for autophagy induction in Tsc2
-/-
 MEFs upon 
SCD-1 inhibition (Fig. 28). The differences observed between the different studies could 
be due to the different cell types utilized, as well as the different cellular stimulus for 
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activation of FoxO1. For example, cytosolic FoxO1 could be important for autophagy 
induction upon nutrient starvation or oxidative stress as reported (Zhao et al., 2010), 
while in our study, the nucleus translocated FoxO1 might only particularly important 
during direct inhibition of Akt activity without affecting MTORC1 signaling pathway.  
4.8 Tsc2
-/-
 MEFs are ‘addicted’ to endogenous MUFA production for cell survival 
and autophagy functions as a cell survival mechanism during SCD-1 inhibition  
Previous studies have shown that inhibition of SCD-1 induces apoptosis in a variety of 
cancer cells (Dobrzyn et al., 2004; Minville-Walz et al., 2010; Scaglia et al., 2009). In 
this study, we reported that Tsc2
-/-
 MEFs are much more susceptible to cell death induced 
by inhibition of SCD-1 enzymatic activity than the Tsc2
+/+
 MEFs while concurrent 
inhibition of autophagy further increased the cell death in the SCD-1 inhibited Tsc2
-/-
 
MEFs (Fig. 29). Our results thus imply that the cells with hyperactivated MTORC1 
signaling are ‘addicted’ to the continual production of endogenous MUFAs for cell 
growth and survival. The dependence of these Tsc2
-/-
 MEFs on particular nutrients like 
glucose and glutamine for cell growth and survival has been reported previously (Choo et 
al., 2010). In this part of our study, we have gone on to show that survival of these cells is 





MEFs is presumably due to the differential metabolic demands between the two cell types 
as a result of the hyperactivated MTORC1 signaling pathway in the Tsc2
-/-
 MEFs (Caron 
et al., 2010; Choo et al., 2010; Duvel et al., 2010). This is consistent with an earlier report 
that transformed cells are more dependent on de novo synthesis of MUFA, rather than the 
exogenous MUFA (Scaglia and Igal, 2005). In contrast, the Tsc2
+/+
 MEFs have a much 
lower metabolic demand for MUFAs and are more likely to get sufficient exogenous 
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source from the culture medium and thus are more resistant to inhibition of SCD-1 
activity. Induction of autophagy in the Tsc2
-/-
 MEFs during SCD-1 inhibition could help 
to generate free MUFAs from the lipid droplets stored within the cells to support the 
aberrant cell growth in the Tsc2
-/-
 MEFs. Furthermore, we observed that levels of TAG, 
which are the main components of lipid droplets were significantly decreased in the Tsc2
-
/-
 MEFs after SCD-1 inhibition (Fig. 21B), suggesting that induction of lipophagy which 
is the degradation of lipid droplets via autophagic machinery might be occurring (Singh 
et al., 2009a). Therefore, inhibition of autophagy will further starve the Tsc2
-/-
 MEFs 
from their required MUFA, thus sensitizing cell death mediated by SCD-1 inhibition. 
Our findings reported here suggest new therapeutic strategies by targeting lipogenesis for 
genetic disorders like TSC which are characterized by the deregulation of MTORC1 
signaling pathway. Recent clinical trials in the treatment of TSC involved the use of 
rapamycin analogs to inhibit the MTORC1 signaling pathway and these inhibitors were 
only able to have cytostatic effects (Bissler et al., 2008). Reappearance of tumour growth 
was observed in the TSC patients when they were taken off these rapamycin analogs 
(Bissler et al., 2008). In contrast, our findings here suggest that instead of trying to inhibit 
the hyperactivated MTORC1 signaling pathway, we can take advantage of this Achilles’ 
heel specifically in the TSC2 deficient cells and target their dependence on endogenous 
MUFAs as a cytotoxic approach to kill the cells. Furthermore, as we have shown, a 
combinational therapy together with autophagy inhibition will further increase the 
efficacy of such treatments, although the efficacy of such combinational approaches 
needs to be further tested.             
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Lipids are the major components of cellular membrane structures and play important 
functions in various cellular signaling pathways. (Vander Heiden et al., 2009; Zoncu et al., 
2011b). Autophagy, on the other hand, is known to be involved in lipid metabolism 
(Singh et al., 2009a). Our study provides novel evidence implicating SCD-1 as a key 
regulator in lipid metabolism and autophagy, especially in cells with high demand of 
lipogenesis due to constitutive activation of MTOR. As depicted in Figure 30, we have 
shown here that under normal conditions, cells deficient of TSC2 protein have 
constitutively activated MTORC1 activity, leading to increased SCD-1 expression and de 
novo lipogenesis required to maintain the enhanced metabolic demands. In the presence 
of intact lipid raft structure, Akt is recruited to plasma membrane to be phosphorylated by 
both PDK1 and MTORC2 to be fully activated. Subsequently, activated Akt 
phosphorylates its downstream target FoxO1 and prevents its nuclear translocation and 
gene expression. When SCD-1 is inhibited either via a chemical inhibitor or siRNA 
knockdown, de novo lipogenesis in the cells is suppressed, leading to disruption of lipid 
raft structures, reduced Akt recruitment to the plasma membrane, and subsequently 
impaired Akt activation and Akt-mediated FoxO1 phosphorylation. The 
unphosphorylated FoxO1 then translocates into the nucleus and activates expression of 
various genes involved in autophagy, a process independent of MTOR regulation. 
Therefore, it appears that SCD-1 plays a critical role in mediating lipogenesis and 
autophagy; both are serving as important pro-survival forces in supporting cells with 





Figure 31: Proposed mechanisms underlying the critical role of SCD-1 in autophagy regulation via 




In summary, data from this part of the study provide novel evidence implicating SCD-1 
in autophagy via a signaling pathway involving lipogenesis, lipid rafts, Akt and FoxO1 
(Fig. 31). Our study suggests that targeting SCD-1 could be a potential cancer therapeutic 
strategy in patients with altered metabolic homeostasis caused by constitutive MTOR 

















In this study, we have investigated how the manipulation of lipids can play a role in the 
regulation of autophagy using different in vitro cell culture models. The whole study 
consists of 2 major parts. In the first part of the study, we have tried to study the role of 
exogenous saturated and unsaturated fatty acids in the regulation of autophagy during 
lipotoxic stresses and the signalling mechanism regulating this fatty acid induced 
autophagy induction. The major findings from the first part of the study are (i) SFAs like 
PA but not MUFAs are able to induce autophagy during lipotoxic stress; (ii) induction of 
autophagy by PA is independent of MTORC1 regulation but is mediated by the DAG-
PKC  signalling pathway; (iii) autophagy plays a cell survival role during lipotoxic stress 
and suppression of autophagy will lead to increased cell death. These major findings have 
been summarized in Figure 30 above.    
In the second part of the study, we have tried to investigate whether modulation of 
endogenous levels of MUFAs and SFAs through inhibition of SCD-1 can affect 
autophagy in using the Tsc2
-/-
 cell model where MTORC1 is constitutively active leading 
to high levels of de novo lipogenesis. The major findings from the second part of the 
study are (i) inhibition of SCD-1 activity leads to autophagy induction only in the Tsc2
-/-
 
MEFs; (ii) induction of autophagy is independent of MTORC1 regulation but mediated 
by the Akt-FoxO1 signaling pathway due to the disruption of lipid rafts; (iii) autophagy 
plays a cell survival role in SCD-1 inhibited Tsc2
-/-
 MEFs and suppression of SCD-1 and 
autophagic activity can further sensitize the cells to cell death. These major findings have 
been summarized in Figure 31 above.  
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Taken together, data from this study have demonstrated that we can regulate autophagy 
levels in cells through the modulation of the exogenous or endogenous sources of lipids, 
specifically free fatty acids under different cellular models. Consistently, we have shown 
that autophagy can be induced in cells upon excessive SFA treatment in times of 
lipotoxic stresses. Furthermore, modulation of endogenous MUFA and SFA via 
suppression of SCD-1 activity in Tsc2
-/-
 MEFs can also induce autophagy. In both 
instances, the induction of autophagy is independent of the classic MTORC1 regulation.  
More importantly, we have also provided compelling evidence showing that induction of 
autophagy is an important cell survival mechanism in both parts of the study.  
At present, the exact roles that free fatty acids and its secondary lipid metabolites play in 
regulation of autophagy in various disease states are still not fully understood. Therefore, 
data from this study has provided novel insight into the intricate relationship between 
lipid homeostasis and autophagy during situations of lipotoxic stresses or hyperactivated 
MTORC1 signaling pathway. Such findings also suggest that modulation of autophagic 
activity can be considered as a therapeutic strategy for therapy in the future. More 
immediate work involving in vivo studies using animal models will be essential to 
confirm the results we have observed in this study. In future, these studies will potentially 
lead to the development of therapeutic strategies that is based on the modulation of 
autophagy either through specific autophagy activators or inhibitors for treatment against 
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